

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2016/079181 A1

(43) International Publication Date

26 May 2016 (26.05.2016)

(51) International Patent Classification:

C07H 21/00 (2006.01) A61K 31/7125 (2006.01)  
A61K 31/712 (2006.01)

Basel (CH). MOISAN, Annie; Bläsiring 12, CH-4057  
Basel (CH).

(21) International Application Number:

PCT/EP2015/076967

(74) Agent: TURNER, Mark; Grenzacherstrasse 124, CH-4070 Basel (CH).

(22) International Filing Date:

18 November 2015 (18.11.2015)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(30) Priority Data:

14193887.8 19 November 2014 (19.11.2014) EP  
14198167.0 16 December 2014 (16.12.2014) EP  
15182401.8 25 August 2015 (25.08.2015) EP  
15191074.2 22 October 2015 (22.10.2015) EP  
15191075.9 22 October 2015 (22.10.2015) EP  
15191076.7 22 October 2015 (22.10.2015) EP

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2016/079181 A1

(54) Title: LNA GAPMER OLIGONUCLEOTIDES COMPRISING CHIRAL PHOSPHOROTHIOATE LINKAGES

(57) Abstract: The present relates to LNA gapmer antisense oligonucleotides which comprise stereodefined phosphoramidite linkages. The use of stereodefined phosphoramidite linkages in LNA gapmers has been found to provide enhanced RNaseH activity, and modifying stereospecificity enables the reduced toxicity, altered biodistribution, and enhanced mismatch discrimination.

LNA GAPMER OLIGONUCLEOTIDES COMPRISING CHIRAL PHOSPHOROTHIOATE  
LINKAGES

FIELD OF INVENTION

The present relates to beta-D-oxy LNA gapmer antisense oligonucleotides which comprise  
5 stereodefined phosphorothioate linkages. The use of stereodefined phosphorothioate  
linkages in beta-D-oxy LNA gapmers has been found to provide enhanced RNaseH activity,  
and modifying stereospecificity enables the reduced toxicity, altered biodistribution, and  
enhanced mismatch discrimination.

BACKGROUND

10 Koziolkiewicz *et al.* (NAR 1995 24; 5000-5005) discloses 15mer DNA phosphorothioate  
oligonucleotides where the phosphorothioate linkages are either [all-Rp] configuration, or  
[all-Sp] configuration, or a random mixture of diastereomers. The [all-Rp] was found to be  
“more susceptible to” RNAaseH dependent degradation compared to the hybrids or [all-Sp]  
oligonucleotides, and was found to have a higher duplex thermal stability. It is suggested  
15 that for practical application, the [all-Rp] oligos should be protected by [Sp]  
phosphorothioates at their 3' end.

Stec *et al.* (J. Am. Chem. Soc. 1998, 120; 7156 – 7167) reports on new monomers of 5'-  
DMT-deoxyribonucleoside 3'-O-(2-thio-“spiro”-4,4-pentamethylene-1,2,3-oxathiaphospholane)  
for use in sterocontrolled synthesis of PS-oligos via the oxathiaphospholane approach.

20 Karwowski *et al.* (Bioorganic & Med. Chem. Letts. 2001 11; 1001-1003) uses the  
oxathiaphospholane approach for the sterocontrolled synthesis of LNA dinucleoside  
phosphorothioates. The R stereoisomer dinucleotide was readily hydrolysed by snake venom  
phosphodiesterase

Krieg *et al.* (Oligonucleotides 13;491-499) investigated whether the immune stimulation by  
25 CpG PS-oligos depend on the chirality of their P-chirality. CpG PS Rp oligos showed much  
higher MAPK activation and induction of I<sub>K</sub>B degradation as compared to Sp oligos. There  
was no evidence for differential uptake of the different stereoisomer oligonucleotides. The Rp  
oligonucleotides had a shorter duration (less than 48hours), probably due to rapid  
degradation. For immune stimulation, CpG oligos with Rp chirality are suggested for rapid  
30 short term use, and the Sp oligos for longer term effect.

Levin *et al.* Chapter 7 Antisense Drug Technology 2008; 183 – 215 reviews phosphorothioates chirality, confirming that the chirality of phosphorothioates DNA oligonucleotides greatly effects their pharmacokinetics, not least due to the exonuclease resistance of the Sp stereoisomer. The PK effects of phosphorothioate chirality are reported

5 to be less significant in second generation ASOs due to the 2' modifications at the 3' and 5' termini which prevents exonuclease degradation, but it is likely that individual molecules which have Rp terminal residues may be more susceptible to exonucleases → *i.e.* for longer half-lives, the molecules with Sp residues at the termini are likely to have longer half-life.

Wave Life Sciences Poster (TIDES, May 3 – 6 2014, San Diego): Based on the calculation 10 of 524,288 possible different stereoisomers within mipomersen they illustrate 7 stereoisomers which differ markedly with respect to Tm, RNaseH recruitment, lipophilicity, metabolic stability, efficacy *in vivo*, and specific activity.

15 Wan *et al.*, Nucleic Acids Research, November 14, 2014 (advanced publication), discloses 31 antisense oligonucleotides where the chirality of the gap region was controlled using the DNA- oxazaphospholine approach (Oka *et al.*, J. Am. Chem. Soc. 2008; 16031 – 16037.) , and concluded that controlling PS chirality in the gap region of gapmers provides no significant benefits for therapeutic applications relative to the mixture of stereo-random PS ASOs. Wan *et al.* further refers to the added complexity and costs associated with the synthesis and characterization of chiral PS ASOs as minimizing their utility.

20 Swayze *et al.*, 2007, NAR 35(2): 687-700 reports that LNA antisense compounds improve potency but cause significant hepatotoxicity in animals. WO 2008/049085 reports on LNA mixed wing gapmers which comprise 2'-O-MOE in the LNA flanking regions, which apparently reduce the toxicity of certain LNA compounds, but significantly reduce the potency.

25 WO2014/012081 and WO2014/010250 provide chiral reagents for synthesis of oligonucleotides.

WO2015/107425 reports on the chiral designs of chirally defined oligonucleotides, and reports that certain chirally defined compounds can alter the RNaseH cleavage pattern.

#### SUMMARY OF INVENTION

30 The invention provides an LNA-gapmer oligonucleotide which comprises at least one stereodefined phosphorothioate internucleoside linkage within the gap region, wherein the LNA-gapmer comprises at least one beta-D-oxy LNA nucleoside unit.

The invention provides an LNA-gapmer oligonucleotide greater than 12 nucleotides in length, which comprises at least one stereodefined phosphorothioate internucleoside linkage within the gap region. In some embodiments the LNA-gapmer comprises at least one beta-D-oxy LNA nucleoside unit or at least one ScET nucleoside unit.

5

In the LNA-gapmer oligonucleotide of the invention, the gapmer oligonucleotide may comprise a central region (Y') of at least 5 or more contiguous nucleosides, such as at least 5 or more DNA nucleosides (or a region which is capable of recruiting RNaseH), and a 5' wing region (X') comprising of 1 – 6 nucleoside analogues such as LNA and/or 2' substituted nucleosides and a 3' wing region (Z') comprising of 1 – 6 nucleoside analogues such as LNA and/or 2' substituted nucleosides. Suitably at least one of region X' and Z' comprises a LNA nucleoside, such as a beta-D-oxy-LNA nucleoside or in some embodiments a ScET nucleoside.

10 15 The invention provides an oligonucleotide comprising a central region (Y') of at least 5 or more contiguous nucleosides, and a 5' wing region (X') comprising of 1 – 6 LNA nucleosides and a 3' wing region (Z') comprising of LNA 1 – 6 nucleosides, wherein at least one of the internucleoside linkages of central region are stereodefined, and wherein the central region comprises both Rp and Sp internucleoside linkages and wherein the oligonucleotide  
20 comprises at least one beta-D-oxy LNA nucleoside unit.

The invention further provides a conjugate comprising the oligomer according to the invention, which comprises at least one non-nucleotide or non-polynucleotide moiety (“conjugated moiety”) covalently attached to the oligomer of the invention.

25

The invention provides for pharmaceutical compositions comprising an oligomer or conjugate of the invention, and a pharmaceutically acceptable solvent (such as water or saline water), diluent, carrier, salt or adjuvant.

30 Pharmaceutical and other compositions comprising an oligomer of the invention are also provided. Further provided are methods of down-regulating the expression of a target nucleic acid, e.g. an RNA, such as a mRNA or microRNA in cells or tissues comprising contacting said cells or tissues, *in vitro* or *in vivo*, with an effective amount of one or more of the oligomers, conjugates or compositions of the invention.

35

Also disclosed are methods of treating an animal (a non-human animal or a human) suspected of having, or susceptible to, a disease or condition, associated with expression, or over-expression of a RNA by administering to the non-human animal or human a therapeutically or prophylactically effective amount of one or more of the oligomers, 5 conjugates or pharmaceutical compositions of the invention.

The invention provides for methods of inhibiting (e.g., by down-regulating) the expression of a target nucleic acid in a cell or a tissue, the method comprising the step of contacting the cell or tissue, *in vitro* or *in vivo*, with an effective amount of one or more oligomers, 10 conjugates, or pharmaceutical compositions thereof, to affect down-regulation of expression of a target nucleic acid.

The invention provides for a phosphorothioate LNA oligonucleotide, comprising at least one stereodefined phosphorothioate linkage between a LNA nucleoside and a subsequent (3') 15 nucleoside. Such an LNA oligonucleotide may for example be a LNA gapmer, such as those as described or claimed herein. Such an oligonucleotide may be described as stereoselective.

In some embodiments, the LNA oligonucleotide of the invention comprises at least one 20 stereodefined phosphorothioate linkage between a LNA nucleoside and a subsequent (3') nucleoside. A stereodefined phosphorothioate linkage may also be referred to as a stereoselective or stereospecific phosphorothioate linkage.

In some embodiments, the LNA oligonucleotide of the invention comprises at least one stereodefined phosphorothioate nucleotide pair wherein the internucleoside linkage between 25 the nucleosides of the stereodefined phosphorothioate nucleotide pair is either in the Rp configuration or in the Rs configuration, and wherein at least one of the nucleosides of the nucleotide pair is a LNA nucleotide. In some embodiments, the other nucleoside of the stereodefined phosphorothioate nucleotide pair is other than DNA, such as nucleoside analogue, such as a further LNA nucleoside or a 2' substituted nucleoside.

30 The invention provides for a stereodefined phosphorothioate oligonucleotide which has a reduced toxicity *in vivo* or *in vitro* as compared to a non-stereodefined phosphorothioate oligonucleotide (parent) with the same nucleobase sequence and chemical modifications (other than the stereodefined phosphorothioate linkage(s)). In some embodiments, the non-

stereodefined phosphorothioate oligonucleotide / stereodefined oligonucleotide may be a gapmer, such as a LNA-gapmer. For the comparison of toxicity, the stereodefined phosphorothioate oligonucleotide retains the pattern of modified and unmodified nucleosides present in the parent oligonucleotide

5

The invention provides for the use of a stereodefined phosphorothioate internucleoside linkage in an oligonucleotide, wherein the oligonucleotide has a reduced toxicity as compared to an identical oligonucleotide which does not comprise the sterospecified phosphorothioate internucleotide linkage.

10 The invention provides for the use of a stereocontrolling phosphoramidite monomer for the synthesis for a reduced toxicity oligonucleotide (a stereodefined phosphorothioate oligonucleotide).

The invention provides a method of altering the biodistribution of an antisense oligonucleotide sequence (parent oligonucleotide), comprising the steps of

15 a. Creating a library of stereodefined oligonucleotide variants (child oligonucleotides), retaining the core nucleobase sequence of the parent oligonucleotide,  
b. Screening the library created in step a. for their biodistribution  
c. Identify one or more stereodefined variants present in the library which has an  
20 altered (such as preferred) biodistribution as compared to the parent oligonucleotide.

It is recognised that in some embodiments, the parent oligonucleotide may be a mixture of different stereoisomeric forms, and as such the method of the invention may comprise a method of identifying individual stereodefined oligonucleotides, or individual stereoisomers  
25 (child oligonucleotides) which have one or more improved property, such as reduced toxicity, enhanced specificity, altered biodistribution, enhanced potency as compared to the parent oligonucleotide.

In some embodiments the compounds of the invention, or identified by the methods of the invention, have an enhanced biodistribution to the liver.

30 In some embodiments the compounds of the invention, or identified by the methods of the invention, have an enhanced liver/kidney biodistribution ratio.

In some embodiments the compounds of the invention, or identified by the methods of the invention, have an enhanced kidney/liver biodistribution ratio.

In some embodiments the compounds of the invention, or identified by the methods of the invention, have an enhanced biodistribution to the kidney.

In some embodiments the compounds of the invention, or identified by the methods of the invention, have an enhanced cellular uptake in hepatocytes.

5 In some embodiments the compounds of the invention, or identified by the methods of the invention, have an enhanced cellular uptake in kidney cells.

When referring to compounds with enhanced functional characteristics, the enhancement may be made with regards the parent oligonucleotide, such as an otherwise identical non-stereodefined oligonucleotide.

10 Whilst biodistribution studies are typically performed *in vivo*, they may also be performed in *in vitro* systems, by example by comparing the cellular uptake in different cell types, for examples in *in vitro* hepatocytes (e.g. primary hepatocytes) or renal cells (e.g. renal epithelial cells, such as PTEC-TERT1 cells).

## 15 FIGURES

**Figure 1:** A schematic view of some LNA oligonucleotide of the invention. The figure shows a 3-10-3 gapmer oligonucleotide with 15 internucleoside phosphorothioate linkages. The internucleoside linkages in the wing regions X' and Y' may be as described herein, for example may be randomly Rp or Sp phosphorothioate linkages. The table part of figure 1 20 provides a parent compound (P) where all the internucleoside linkages of the gap region Y' are also randomly incorporated Rp or Sp phosphorothioate linkages (M), and in compounds 1 – 10, one of the phosphorothioate linkages is stereodefined as a Rp phosphorothioate internucleoside linkage (R).

**Figure 2:** As per figure 1, except in compounds 1 – 10, one of the phosphorothioate 25 linkages is stereodefined as a Sp phosphorothioate internucleoside linkage (S).

**Figure 3:** The hepatotoxic potential (ALT) for LNA oligonucleotides where 3 phosphorothioate internucleoside linkages are fixed in either S (Comp #10) or R (Comp #14) configuration was compared to the ALT for parent mixture of diastereoisomers (Comp #1) with all internucleoside linkages as mixtures of R and S configuration.

30 **Figure 4:** Oligonucleotide content in liver, kidney, and spleen

**Figure 5:** Changes in LDH levels in the supernatants and intracellular ATP levels of cells treated for 3 days with the respective LNAs. Target knockdown (Myd88) was evaluated after 48hours.

**Figure 6:** In vitro toxicity screening in primary hepatocytes: Changes in LDH levels in the supernatants and intracellular ATP levels of cells treated for 3 days with the respective LNAs. Data are mean values and expressed as % vehicle control (n=4 experiments in triplicates for #56 and n=2 experiments in triplicates for all other LNAs).

5 **Figure 7:** In vitro toxicity screening in kidney proximal tubule cells: Viability of PTEC-TERT1 treated with LNA Myd88 stereovariants at 10 $\mu$ M and 30 $\mu$ M as measured after 9 days (cellular ATP).

## DETAILED DESCRIPTION OF INVENTION

### *The Oligomer*

10 The present invention provides oligomeric compounds (also referred herein as oligomers or oligonucleotides) for use in modulating, such as inhibiting a target nucleic acid in a cell. The oligomers may be a gapmer oligonucleotide.

In some embodiments the oligonucleotide of the invention is 10 – 20 nucleotides in length, such as 10 – 16 nucleotides in length. In some embodiments the oligonucleotide of the

15 invention is 12 – 20 or 12 – 24 nucleotides in length, such as 12 – 20 or 12 – 24 nucleotides in length.

Oligonucleotides which comprise at least one LNA nucleoside may be referred to as an LNA oligonucleotide or LNA oligomer herein.

20 The invention provides a gapmer oligonucleotide comprising a central region (Y') of at least 5 or more contiguous nucleosides, and a 5' wing region (X') comprising of 1 – 6 LNA or 2' substituted nucleosides and a 3' wing region (Z') comprising of LNA 1 – 6 or 2' substituted nucleosides, wherein at least one of the internucleoside linkages of central region is stereodefined, and wherein the central region comprises both Rp and Sp internucleoside linkages; and wherein at least one of the LNA or 2' substituted nucleosides region (X') or (Z') is a beta-D-oxy LNA nucleoside. The oligonucleotide of the invention is therefore an LNA oligonucleotide.

25 The gapmer oligonucleotide of the invention may comprise a central region (Y') of at least 5 or more contiguous nucleosides capable of recruiting RNaseH, and a 5' wing region (X') comprising of 1 – 6 LNA nucleosides and a 3' wing region (Z') comprising of LNA 1 – 6 nucleosides, wherein at least one of the internucleoside linkages of central region are stereodefined, and wherein the central region comprises both Rp and Sp internucleoside linkages. Suitably region Y' may have 6, 7, 8, 9, 10, 11 or 12 (or in some embodiments 13,

14, 15 or 16) contiguous nucleotides, such as DNA nucleotides, and the nucleotides of regions X' and Z' adjacent to region Y' are LNA nucleotides. In some embodiments regions X' and Z' have 1-6 nucleotides at least one of which in each flank (X' and Z') are an LNA. In some embodiments all the nucleotides in region X' and region Z' are LNA nucleotides. In 5 some embodiments the oligonucleotide of the invention comprises LNA and DNA nucleosides. In some embodiments, the oligonucleotide of the invention may be a mixed wing LNA gapmer where at least one of the LNA nucleosides in one of the wing regions (or at least one LNA in each wing) is replaced with a DNA nucleoside, or a 2' substituted nucleoside, such as a 2' MOE nucleoside. In some embodiments the LNA gapmer does not 10 comprise 2' substituted nucleosides in the wing regions.

The internucleoside linkages between the nucleotides in the contiguous sequence of nucleotides of regions X'-Y'-Z' may be all phosphorothioate internucleoside linkages. In some embodiments, the internucleoside linkages within region Y' are all stereodefined phosphorothioate internucleoside linkages. In some embodiments, the internucleoside 15 linkages within region X' and Y' are stereodefined phosphorothioate internucleoside linkages. In some embodiments the internucleoside linkages between region X' and Y' and between region Y' and Z' are stereodefined phosphorothioate internucleoside linkages. In some embodiments all the internucleoside linkages within the contiguous nucleosides of regions X'-Y'-Z' are stereodefined phosphorothioate internucleoside linkages.

20 The introduction of at least one stereodefined phosphorothioate linkage in the gap region of an oligonucleotide (optionally including the introduction of at least one stereodefined phosphorothioate linkages adjacent to a LNA nucleoside, or in the one or both wing regions) may be used to modulate the biological profile of the oligonucleotide, for example it may 25 modulate the toxicity profile. In some embodiments, 2, 3, 4 or 5 of the phosphorothioate linkages in the gap region are stereodefined. In some embodiments the remaining internucleoside linkages in the gap region are not stereodefined: They exist as a (e.g. racemic) mixture of Rp and Sp in the population of oligonucleotide species. In some embodiments the remaining internucleoside linkage in the oligonucleotide are not 30 stereodefined. In some embodiments all the internucleoside linkages in the gap region are stereodefined. The gap region (referred to as Y') herein, is a region of nucleotides which is capable of recruiting RNaseH, and may for example be a region of at least 5 contiguous DNA nucleosides. In some embodiments all the internucleoside linkages in the gap and wing regions are stereodefined (*i.e.* within X'-Y'-Z'). In some embodiments all of the 35 phosphorothioate internucleoside linkages in the oligonucleotide of the invention are

stereodefined phosphorothioate internucleoside linkages. In some embodiments, all of the internucleoside linkages in the oligonucleotide of the invention are stereodefined phosphorothioate internucleoside linkages.

Typically, oligonucleotide phosphorothioates are synthesised as a random mixture of

5 Rp and Sp phosphorothioate linkages (also referred to as a racemic mixture). In the present invention, gapmer phosphorothioate oligonucleotides are provided where at least one of the phosphorothioate linkages of the gap region oligonucleotide is stereodefined, *i.e.* is either Rp or Sp in at least 75%, such as at least 80%, or at least 85%, or at least 90% or at least 95%, or at least 97%, such as at least 98%, such as at least 99%, or (essentially) all of the  
10 oligonucleotide molecules present in the oligonucleotide sample. Such oligonucleotides may be referred as being stereodefined, stereoselective or stereospecified: They comprise at least one phosphorothioate linkage which is stereospecific. The terms stereodefined and stereospecified / stereoselective may be used interchangeably herein. The terms stereodefined, stereoselective and stereospecified may be used to describe a  
15 phosphorothioate internucleoside linkage (Rp or Sp), or may be used to described a oligonucleotide which comprises such a phosphorothioate internucleoside linkage. It is recognised that a stereodefined oligonucleotide may comprise a small amount of the alternative stereoisomer at any one position, for example Wan et al reports a 98% stereoselectivity for the gapmers reported in NAR, November 2014.  
20 In some embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, of the linkages in the gap region of the oligomer are stereodefined phosphorothioate linkages.

In some embodiments 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the linkages in the oligomer are stereodefined

25 phosphorothioate linkages. In some embodiments all of the phosphorothioate linkages in the oligomer are stereodefined phosphorothioate linkages. In some embodiments the all the internucleoside linkages of the oligomer are stereodefined phosphorothioate linkages. It should be recognised that stereodefined (stereospecificity) refers to the incorporation of a high proportion, *i.e.* at least 75%, of either the Rp or the Sp internucleoside linkage at a  
30 defined internucleoside linkage.

LNA monomers (also referred to as bicyclic nucleic acids, BNA) are nucleosides where there is a biradical between the 2' and 4' position of the ribose ring. The 2' – 4' biradical is also referred to as a bridge. LNA monomers, when incorporated into a oligonucleotides are

35 known to enhance the binding affinity of the oligonucleotide to a complementary DNA or

RNA sequence, typically measured or calculated as an increase in the temperature required to melt the oligonucleotide/target duplex ( $T_m$ ).

An LNA oligomer comprises at least one “Locked Nucleic Acid” (LNA) nucleoside, such as a nucleoside which comprises a covalent bridge (also referred to a radical) between 5 the 2' and 4' position (a 2' – 4' bridge). LNA nucleosides are also referred to as “bicyclic nucleosides”. The LNA oligomer is typically a single stranded antisense oligonucleotide.

In some embodiments the LNA oligomer comprises or is a gapmer. In some embodiments, the nucleoside analogues present in the oligomer are all LNA.

In various embodiments, the compound of the invention does not comprise RNA 10 (units). In some embodiments, the oligomer has a single contiguous sequence which is a linear molecule or is synthesized as a linear molecule. The oligomer may therefore be single stranded molecule. In some embodiments, the oligomer does not comprise short regions of, for example, at least 3, 4 or 5 contiguous nucleotides, which are complementary to equivalent regions within the same oligomer (*i.e.* duplexes). The oligomer, in some 15 embodiments, may be not (essentially) double stranded. The oligomer is essentially not double stranded, such as is not a siRNA. In some embodiments, the oligomeric compound is not in the form of a duplex with a (substantially) complementary oligonucleotide – e.g. is not an siRNA.

The term “oligomer” in the context of the present invention, refers to a molecule 20 formed by covalent linkage of two or more nucleotides (*i.e.* an oligonucleotide). Herein, a single nucleotide (unit) may also be referred to as a monomer or unit. In some embodiments, the terms “nucleoside”, “nucleotide”, “unit” and “monomer” are used interchangeably. It will be recognized that when referring to a sequence of nucleotides or 25 monomers, what is referred to is the sequence of bases, such as A, T, G, C or U. The term monomer is used herein both to describe each unit of an oligonucleotide (nucleoside/nucleotide) as well as the (phosphoramidite) monomers used in oligonucleotide synthesis.

### **Advantages**

#### **30 RNaseH Recruitment**

As illustrated in the examples, in some embodiments, the stereodefined oligonucleotides of the invention have an enhanced RNaseH recruitment activity as compared to an otherwise non-stereodefined oligonucleotide (the parent oligonucleotide). Indeed, the present inventors were surprised to find that in general, the introduction of stereodefined

phosphorothioate internucleoside linkages into a RNaseH recruiting LNA oligonucleotide, e.g. a LNA gapmer oligonucleotide, resulted in an enhanced RNaseH recruitment activity, upto 30x that of the parent (non-stereodefined). The invention therefore provides for the use of a stereocontrolled (also refered to as stereospecific) phosphoramidite monomer for the

5 synthesis for an oligonucleotide with enhanced RNaseH recruitment activity as compared to an otherwiseidentical non-stereodefined oligonucleotide.

The invention provides for a method for enhancing the RNaseH recruitment activity of an antisense oligonucleotide sequence (parent oligonucleotide) for a RNA target, comprising the steps of:

- 10    a.        Creating a library of stereodefined oligonucleotide variants (child oligonucleotides), retaining the core nucleobase sequence of the parent oligonucleotide
- b.        Screening the library created in step a. for their in vitro RNaseH recruitment activity against a RNA target,
- c.        Identify one or more stereodefined variants present in the library which has an enhanced RNaseH recruitment activity as compared to the parent oligonucleotide.
- 15    d.        Optionally manufacturing at least one of the stereodefined variants identified in step c.

The invention provides for an LNA oligonucleotide which has an enhanced RNaseH recruitment activity as compared to an otherwise identical non-stereodefined LNA oligonucleotide (or a parent oligonucleotide).

- 20    An otherwise identical non-stereodefined LNA oligonucleotide (e.g. a parent oligonucleotide) is a non-stereodefined phosphorothioate oligonucleotide with the same nucleobase sequence and chemical modifications, other than the stereodefined phosphorothioate linkage(s). It will be recognised that a non-stereodefined LNA oligonucleotide may comprise stereodefined centres in parts of the compound other than the phosphorothioate
- 25    internucleotide linkages, e.g. within the nucleosides.

The use of chirally defined phosphorothioate linkages in LNA oligonucleotides surprisingly results in an increase in RNaseH activity. This may be seen when the gap-region comprises both stereodefined Rp and Sp internucleoside linkages. In some embodiments, the gap-region of the oligonucleotide of the invention comprises at least 2 Rp and at least 2 Sp stereodefined internucleoside linkages. In some embodiments the proportion of Rp vs. Sp stereodefined internucleoside linkages within gap region thereof (including internucleoside linkages adjacent to the wing regions), is between about 0.25 and about 0.75. In some embodiments, the gap-region of the oligonucleotide of the invention comprises at least 2 consecutive internucleoside linkages which are either stereodefined Rp or Sp

internucleoside linkages. In some embodiments, the gap-region of the oligonucleotide of the invention comprises at least 3 consecutive internucleoside linkages which are either stereodefined Rp or Sp internucleoside linkages.

In some embodiments, the LNA oligonucleotide has an enhanced human RNaseH recruitment activity as compared to an equivalent non stereoselective LNA oligonucleotide, for example using the RNaseH recruitment assays provided in example 7. In some embodiments, the increase in RNaseH activity is at least 2x, such as at least 5x, such as at least 10x the RNaseH activity of the equivalent non stereoselective LNA oligonucleotide (e.g. parent oligonucleotide). Example 7 provides a suitable RNaseH assay which may be used to assess RNaseH activity (also referred to as RNaseH recruitment).

It has been found that a marked improvement in activity of RNaseH activity is found with LNA gapmer compounds where the gap region comprises both Rp and Sp internucleoside linkages, and in some embodiments, the gap region may comprise at least two Rp internucleoside linkages and at least two Sp internucleoside linkages, such as at least three Rp internucleoside linkages and/or at least three Sp internucleoside linkages.

It has been found that a marked improvement in activity of RNaseH activity is found with LNA gapmer compounds where the internucleoside linkages of the gap region are stereodefined. In some embodiments, therefore, there is at least one stereoselective phosphorothioate LNA oligonucleotide, comprising at least one stereoselective phosphorothioate linkage between a LNA nucleoside and a subsequent (3') nucleoside. In some embodiments at least one of the internucleotide linkages within region X' and / or Z' is a Rp internucleoside linkage. In some embodiments, the 5' most internucleoside linkage in the oligomer or in region X' is a Sp internucleoside linkage. In some embodiments the flanking regions X' and Z' comprise at least one Sp internucleoside linkage and at least one Rp internucleoside linkage. In some embodiments the 3' internucleoside linkage of the oligomer or of region Z' is a Sp internucleoside linkage.

In some embodiments, the stereodefined oligonucleotide of the invention has improved potency as compared to an otherwise non-stereodefined oligonucleotide or parent oligonucleotide.

30 *Specificity and mismatch discrimination*

As illustrated in the examples, in some embodiments, the stereodefined oligonucleotides of the invention may have an enhanced mismatch discrimination (or enhanced target

specificity) as compared to an otherwise non-stereodefined oligonucleotide (or parent oligonucleotide). Indeed, the present inventors were surprised to find that the introduction of stereodefined phosphorothioate internucleoside linkages into a RNaseH recruiting LNA oligonucleotide, e.g. a LNA gapmer oligonucleotide, may result in an enhanced mismatch discrimination (or target specificity). The invention therefore provides for the use of a stereocontrolling phosphorothioate monomer for the synthesis for an oligonucleotide with enhanced mismatch discrimination (or target specificity) as compared to an otherwise identical non-stereodefined oligonucleotide.

10 The invention therefore provides for method of enhancing the mismatch discrimination (or target specificity) of an antisense oligonucleotide sequence (parent oligonucleotide) for a RNA target in a cell, comprising the steps of

- Creating a library of stereodefined oligonucleotide variants (child oligonucleotides), retaining the core nucleobase sequence of the parent oligonucleotide
- 15 Screening the library created in step a. for their activity against the RNA target and their activity for at least one other RNA present,
- c. Identify one or more stereodefined variants present in the library which has a reduced activity against the at least one other RNA as compared to parent oligonucleotide. The reduced activity against the at least one other RNA may be determined as a ratio of

20 activity of the intended target/unintended target (at least one other RNA). This method may be combined with the method for enhancing the RNaseH recruitment activity of an antisense oligonucleotide sequence (parent oligonucleotide) for a RNA target, to identify oligonucleotides of the invention which have both enhanced RNaseH recruitment activity and enhanced mismatch discrimination (i.e. enhanced targeted specificity).

25 The invention provides for an LNA oligonucleotide which has an enhanced mismatch discrimination (or enhanced target specificity) as compared to an otherwise identical non-stereodefined LNA oligonucleotide (or a parent oligonucleotide).

The invention provides for an LNA oligonucleotide which has an enhanced RNaseH recruitment activity and an enhanced mismatch discrimination (or enhanced target

30 specificity) as compared to an otherwise identical non-stereodefined LNA oligonucleotide (or a parent oligonucleotide).

The invention therefore provides for the use of a stereocontrolling/stereocontrolled (can also be referred to as a stereodefined or stereospecific) phosphoramidite monomer for the synthesis for an oligonucleotide with enhanced mismatch discrimination (or target specificity)

and enhanced RNaseH recruitment activity as compared to an otherwise identical non-stereodefined oligonucleotide.

In some embodiments the stereocontrolling phosphoramidite monomer is a LNA stereospecific phosphoramidite monomer. In some embodiments the stereocontrolling 5 phosphoramidite monomer is a DNA stereocontrolling phosphoramidite monomer. In some embodiments the stereospecific phosphoramidite monomer is a 2'-modified stereospecific phosphoramidite monomer, such as a 2'-methoxyethyl stereospecific phosphoramidite RNA monomer. Stereospecific phosphoramidite monomers may, in some embodiments, be 10 oxazaphospholine monomers, such as DNA-oxazaphospholine LNA-oxazaphospholine monomers. In some embodiments, the stereospecific phosphoramidite monomers may comprise a nucleobase selected from the group consisting of A, T, U, C, 5-methyl-C or G nucleobase.

#### *In vivo optimisation*

The present invention provides a method for optimising oligonucleotides, such as 15 oligonucleotides identified by gene-walk for in vivo (e.g. pharmacological) utility. In particular the monomers of the present invention may be used in the synthesis of oligomers to enhance beneficial *in vivo* properties, such as serum protein binding, biodistribution, intracellular uptake, or to reduce undesirable properties, such as toxicity or inflammatory sensitivities.

#### *Reduced Toxicity*

The invention provides a method of reducing the toxicity of an antisense oligonucleotide sequence (parent oligonucleotide), comprising the steps of

- a. Creating a library of stereodefined oligonucleotide variants (child oligonucleotides), retaining the core nucleobase sequence of the parent 25 oligonucleotide,
- b. Screening the library created in step a. for their in vitro or in vivo toxicity in a cell,
- c. Identify one or more stereodefined variants present in the library which has a reduced toxicity in the cell as compared to the parent oligonucleotide.

In some embodiments the reduced toxicity is reduced hepatotoxicity. Hepatotoxicity of an 30 oligonucleotide may be assess *in vivo*, for example in a mouse. *In vivo* hepatotoxicity assays are typically based on determination of blood serum markers for liver damage, such as ALT, AST or GGT. Levels of more than three times upper limit of normal are considered to be indicative of *in vivo* toxicity. *In vivo* toxicity may be evaluated in mice using, for

example, a single 30mg/kg dose of oligonucleotide, with toxicity evaluation 7 days later (7 day *in vivo* toxicity assay).

Suitable markers for cellular toxicity include elevated LDH, or a decrease in cellular ATP,

5 and these markers may be used to determine cellular toxicity *in vitro*, for example using primary cells or cell cultures. For determination of hepatotoxicity, mouse or rat hepatocytes may be used, including primary hepatocytes. Primary primate such as human hepatocytes may be used if available. In mouse hepatocytes an elevation of LDH is indicative of toxicity. A reduction of cellular ATP is indicative of toxicity. In some embodiments the

10 oligonucleotides of the invention have a reduced *in vitro* hepatotoxicity, as determined in primary mouse hepatocyte cells, e.g. using the assay provided in Example 8.

In some embodiments the reduced toxicity is reduced nephrotoxicity. Nephrotoxicity may be assessed *in vivo*, by the use of kidney damage markers including a rise in blood serum creatinine levels, or elevation of kim-1 mRNA/protein. Suitably mice or rodents may be

15 used.

*In vitro* kidney injury assays may be used to measure nephrotoxicity, and may include the elevation of kim-1 mRNA/protein, or changes in cellular ATP (decrease). In some embodiments, PTEC-TERT1 cells may be used to determine nephrotoxicity *in vitro*, for example by measuring cellular ATP levels. In some embodiments the oligonucleotides of

20 the invention have a reduced *in vitro* nephrotoxicity, as determined in PTEC-TERT1 cells, e.g. using the assay provided in Example 9.

Other *in vitro* toxicity assays which may be used to asses toxicity include caspase assays, and cell viability assays, e.g. MTS assays. In some embodiments the reduced toxicity oligonucleotide of the invention comprises at least one stereodefined Rp internucleotide

25 linkage, such as at least 2, 3, or 4 stereodefined Rp internucleotide linkage. The examples illustrate compounds which comprise stereodefined Rp internucleotide linkages that have a reduced hepatotoxicity *in vitro* and *in vivo*. In some embodiments, the at least one stereodefined Rp internucleotide linkage is present within the gap-region of a LNA gapmer.

In some embodiments the reduced toxicity oligonucleotide of the invention comprises at 30 least one stereodefined Sp internucleotide linkage, such as at least 2, 3, or 4 stereodefined Sp internucleotide linkage. The examples illustrate compounds which have a reduced nephrotoxicity which comprise at least one stereodefined Sp internucleoside linkage. In some embodiments, the at least one stereodefined Sp internucleotide linkage is present within the gap-region of a LNA gapmer.

The invention provides for the use of a stereocontrolled (may also be referred to as stereospecific, or stereospecifying) phosphoramidite monomer for the synthesis for a reduced toxicity oligonucleotide, e.g. reduced hepatotoxicity or reduced nephrotoxicity oligonucleotide. In some embodiments the stereocontrolled phosphoramidite monomer is a

5 LNA stereocontrolled phosphoramidite monomer. In some embodiments the stereocontrolled phosphoramidite monomer is a DNA stereocontrolled phosphoramidite monomer. In some embodiments the stereocontrolled phosphoramidite monomer is a 2'modified stereocontrolled phosphoramidite monomer, such as a 2'methoxyethyl stereocontrolled phosphoramidite RNA monomer. Stereocontrolled phosphoramidite  
10 monomers may, in some embodiments, be oxazaphospholine monomers, such as DNA-oxazaphospholine LNA-oxazaphospholine monomers.

The monomers of the present invention may be used to reduce hepatotoxicity of LNA oligonucleotides *in vitro* or *in vivo*.

LNA hepatotoxicity may be determined using a model mouse system, see for example EP 1  
15 984 381. The monomers of the present invention may be used to reduce nephrotoxicity of LNA oligonucleotides. LNA nephrotoxicity may be determined using a model rat system, and is often determined by the use of the Kim-1 biomarker (see e.g. WO 2014118267). The monomers of the present invention may be used to reduce the immunogenicity of an LNA oligomer *in vivo*. According to EP 1 984 381, LNAs with a 4'-CH<sub>2</sub>-O-2' radicles are  
20 particularly toxic.

The oligonucleotides of the invention may have improved nuclease resistance, biostability, target affinity, RNaseH activity, and/or lipophilicity. As such the invention provides methods for both enhancing the activity of the oligomer *in vivo* and improvement of the pharmacological and/or toxicological profile of the oligomer.

25 In some embodiments, the LNA oligonucleotide has reduced toxicity as compared to an equivalent non stereoselective LNA oligonucleotide, e.g. reduced *in vivo* hepatotoxicity, for example as measured using the assay provided in example 6, or reduced *in vitro* hepatotoxicity, for example as measured using the assay provided in example 8, or reduced nephrotoxicity, for example as measured using the assay provided in example 9. Reduced  
30 toxicity may also be assessed using other methods known in the art, for example caspase assays and primary hepatocyte toxicity assays (e.g. example 8).

***The Target***

The target of an oligonucleotide is typically a nucleic acid to which the oligonucleotide is capable of hybridising under physiological conditions. The target nucleic acid may be, for example a mRNA or a microRNA (encompassed by the term target gene). Such as

5 oligonucleotide is referred to as an antisense oligonucleotide.

Suitably the oligomer of the invention is capable of down-regulating (e.g. reducing or removing) expression of the a target gene. In this regards, the oligomer of the invention can affect the inhibition of the target gene, typically in a mammalian such as a human cell.. In

10 some embodiments, the oligomers of the invention bind to the target nucleic acid and affect

inhibition of expression of at least 10% or 20% compared to the normal expression level, more preferably at least a 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% inhibition

compared to the normal expression level (such as the expression level in the absence of the oligomer(s) or conjugate(s)). In some embodiments, such modulation is seen when using from 0.04 and 25nM, such as from 0.8 and 20nM concentration of the compound of the

15 invention. In the same or a different embodiment, the inhibition of expression is less than 100%, such as less than 98% inhibition, less than 95% inhibition, less than 90% inhibition, less than 80% inhibition, such as less than 70% inhibition. Modulation of expression level may be determined by measuring protein levels, e.g. by the methods such as SDS-PAGE followed by western blotting using suitable antibodies raised against the target protein.

20 Alternatively, modulation of expression levels can be determined by measuring levels of mRNA, e.g. by northern blotting or quantitative RT-PCR. When measuring via mRNA levels, the level of down-regulation when using an appropriate dosage, such as from 0.04 and 25nM, such as from 0.8 and 20nM concentration, is, In some embodiments, typically to a level of from 10-20% the normal levels in the absence of the compound, conjugate or

25 composition of the invention.

The invention therefore provides a method of down-regulating or inhibiting the expression of a target protein and/or target RNA in a cell which is expressing the target protein and/or RNA, said method comprising administering the oligomer or conjugate according to the invention to said cell to down-regulating or inhibiting the expression of the

30 target protein or RNA in said cell. Suitably the cell is a mammalian cell such as a human cell. The administration may occur, in some embodiments, *in vitro*. The administration may occur, in some embodiments, *in vivo*.

The oligomers may comprise or consist of a contiguous nucleotide sequence which corresponds to the reverse complement of a nucleotide sequence present in the target

35 nucleic acid.

In determining the degree of "complementarity" between oligomers of the invention (or regions thereof) and the target region of the nucleic acid the degree of "complementarity" (also, "homology" or "identity") is expressed as the percentage identity (or percentage homology) between the sequence of the oligomer (or region thereof) and the sequence of 5 the target region (or the reverse complement of the target region) that best aligns therewith. The percentage is calculated by counting the number of aligned bases that are identical between the 2 sequences, dividing by the total number of contiguous monomers in the oligomer, and multiplying by 100. In such a comparison, if gaps exist, it is preferable that such gaps are merely mismatches rather than areas where the number of monomers within 10 the gap differs between the oligomer of the invention and the target region.

As used herein, the terms "homologous" and "homology" are interchangeable with the terms "identity" and "identical".

The terms "corresponding to" and "corresponds to" refer to the comparison between the nucleotide sequence of the oligomer (*i.e.* the nucleobase or base sequence) or 15 contiguous nucleotide sequence (a first region) and the equivalent contiguous nucleotide sequence of a further sequence selected from either i) a sub-sequence of the reverse complement of the nucleic acid target, such as the mRNA which encodes the target protein. WO2014/118267 provides numerous target mRNAs which are of therapeutic relevance, as well as oligomer sequences which may be optimised using the present invention (see e.g. 20 table 1, the NCBI Genbank references are as disclosed in WO2014/118257)

**Table 1**

The compound of the invention may target a nucleic acid (e.g. mRNA encoding, or miRNA) selected from the groups consisting of	For the treatment of a disease or disorder such as
<i>AAT</i>	AAT-LivD
<i>ALDH2</i>	Alcohol dependence
<i>HAMP</i> pathway	Anemia or inflammation /CKD
<i>Apo(a)</i>	Atherosclerosis/high Lp(a)
<i>Myc</i>	Liver cancer
5'UTR	HCV
5'UTR & NS5B	HCV
<i>NS3</i>	HCV
<i>TMPRSS6</i>	Hemochromatosis
Antithrombin III	Hemophilia A, B
<i>ApoCIII</i>	Hypertriglyceridemia
<i>ANGPLT3</i>	Hyperlipidaemia
<i>MTP</i>	Hyperlipidaemia
<i>DGAT2</i>	NASH

<i>ALAS1</i>	Porphyria
Antithrombin III	Rare Bleeding disorders
<i>Serum amyloid A</i>	SAA-amyloidosis
Factor VII	Thrombosis
Growth hormone receptor	Acromegaly
<i>ApoB-100</i>	Hypercholesterolemia
<i>ApoCIII</i>	Hypertriglyceridemia
<i>PCSK9</i>	Hypercholesterolemia
<i>CRP</i>	Inflammatory disorders
<i>KSP or VEGF</i>	Liver cancer
<i>PLK1</i>	Liver cancer
<i>FGFR4</i>	Obesity
Factor IXa	Thrombosis
Factor XI	Thrombosis
<i>TTR</i>	TTR amyloidosis
<i>GCCR</i>	Type 2 diabetes
<i>PTP-1B</i>	Type 2 diabetes
<i>GCGR</i>	Cushing's Syndrome
Hepatic Glucose 6-Phosphate Transporter-1	glucose homeostasis, diabetes, type 2 diabetes

In one embodiment, the target is selected from the group consisting of Myd88, ApoB, and PTEN.

The terms "corresponding nucleotide analogue" and "corresponding nucleotide" are intended to indicate that the nucleotide in the nucleotide analogue and the naturally occurring nucleotide are identical. For example, when the 2-deoxyribose unit of the nucleotide is linked to an adenine, the "corresponding nucleotide analogue" contains a pentose unit (different from 2-deoxyribose) linked to an adenine.

The terms "reverse complement", "reverse complementary" and "reverse complementarity" as used herein are interchangeable with the terms "complement", "complementary" and "complementarity".

### ***Length***

The oligomer may consists or comprises of a contiguous nucleotide sequence of from 7 – 30, such as 7 – 26 or 8 – 25, such as 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides in length, such as 10 – 20 nucleotides in length. In some embodiments, the length of the LNA oligomer is 10 – 16 nucleotides, such as 12, 13 or 14 nucleosides.

In some embodiments, the oligomers comprise or consist of a contiguous nucleotide sequence of a total of from 10 – 22, such as 12 – 18, such as 13 – 17 or 12 – 16, such as 13, 14, 15, 16 contiguous nucleotides in length.

In some embodiments, the oligomers comprise or consist of a contiguous nucleotide

5 sequence of a total of 10, 11, 12, 13, or 14 contiguous nucleotides in length.

In some embodiments, the oligomer according to the invention consists of no more than 22 nucleotides, such as no more than 20 nucleotides, such as no more than 18 nucleotides, such as 15, 16 or 17 nucleotides. In some embodiments the oligomer of the invention comprises less than 20 nucleotides. It should be understood that when a range is given for an oligomer, or contiguous nucleotide sequence length it includes the lower and upper lengths provided in the range, for example from (or between) 10 – 30, includes both 10 and 30.

In some embodiments, the oligomers has a length of less than 20, such as less than 18, such as 16nts or less or 15 or 14nts or less. LNA oligomers often have a length less than 20.

In some embodiments, the oligomers comprise or consist of a contiguous nucleotide sequence of a total of 10, 11, 12, 13, or 14 contiguous nucleotides in length.

In some embodiments, the oligomer according to the invention consists of no more than 22 nucleotides, such as no more than 20 nucleotides, such as no more than 18 nucleotides, such as 15, 16 or 17 nucleotides. In some embodiments the oligomer of the invention comprises less than 20 nucleotides. It should be understood that when a range is given for an oligomer, or contiguous nucleotide sequence length it includes the lower and upper lengths provided in the range, for example from (or between) 10 – 30, includes both 10 and 30.

25

## **Screening Methods**

The invention provides for a method of reducing the toxicity of a stereo unspecified phosphorothioate oligonucleotide sequence, comprising the steps of:

- a. Providing a stereo unspecified phosphorothioate oligonucleotide (the parent) which has a toxicity phenotype in vivo or in vitro
- 30 b. Creating a library of stereo specified phosphorothioate oligonucleotides (the children), retaining the core nucleobase sequence of the parent gapmer oligonucleotide
- c. Screening the library created in step b. in an in vivo or in vitro toxicity assay to

d. Identify one or more stereo specified phosphorothioate oligonucleotides which have a reduced toxicity as compared to the stereo unspecified phosphorothioate oligonucleotide.

The stereo specified phosphorothioate oligonucleotides may be as according to the oligonucleotides of the invention, as disclosed herein. In some embodiments, the parent

5 oligonucleotide is a gapmer oligonucleotide, such as a LNA gapmer oligonucleotide as disclosed herein. In some embodiments, the library of stereo specified phosphorothioate oligonucleotides comprises of at least 2, such as at least 5 or at least 10 or at least 15 or at least 20 stereodefined phosphorothioate oligonucleotides.

The screening method may further comprise a step of screening the children

10 oligonucleotides for at least one other functional parameter, for example one or more of RNaseH recruitment activity, RNase H cleavage specificity, biodistribution, target specificity, target binding affinity, and/or *in vivo* or *in vitro* potency.

The method of the invention may therefore be used to reduce the toxicity associated with the parent oligonucleotide. Toxicity of oligonucleotides may be evaluated *in vitro* or *in vivo*. In

15 *vitro* assays include the caspase assay (see e.g. the caspase assays disclosed in WO2005/023995) or hepatocyte toxicity assays (see e.g. Soldatow et al., *Toxicol Res (Camb)*. 2013 Jan 1; 2(1): 23–39.). *In vivo* toxicities are often identified in the pre-clinical screening, for example in mouse or rat. *In vivo* toxicity be for hepatotoxicity, which is typically measured by analysing liver transaminase levels in blood serum, e.g. ALT and/or

20 AST, or may for example be nephrotoxicity, which may be assayed by measuring a molecular marker for kidney toxicity, for example blood serum creatinine levels, or levels of the kidney injury marker mRNA, kim-1. Cellular ATP levels may be used to determine cellular toxicity, such as hepatotoxicity or nephrotoxicity.

25 The selected child oligonucleotides identified by the screening method are therefore safer effective antisense oligonucleotides.

### ***Stereocontrolled monomer***

A stereocontrolled monomer is a monomer used in oligonucleotide synthesis which confers a stereodefined phosphorothioate internucleoside linkage in the oligonucleotide, *i.e.* either the Sp or Rp. In some embodiments the monomer may be a amidite such as a phosphoramidite. Therefore monomer may, in some embodiments be a stereocontrolling/controlled amidite, such as a stereocontrolling/controlled phosphoramidite. Suitable monomers are provided in the examples, or in the Oka et al., *J. AM. CHEM. SOC.* 2008, 130, 16031–16037 9 16031. See also WO10064146, WO 11005761, WO 13012758,

WO 14010250, WO 14010718, WO 14012081, and WO 15107425. The term stereocontrolled/stereocontrolling are used interchangeably herein and may also be referred to stereospecific/stereospecified or stereodefined monomers.

As the stereocontrolled monomer may therefore be referred to as a stereocontrolled

5 "phosphorothioate" monomer. The term stereocontrolled and stereocontrolling are used interchangeably herein. In some embodiments, a stereocontrolling monomer, when used with a sulfarizing agent during oligonucleotide synthesis, produces a stereodefined internucleoside linkage on the 3' side of the newly incorporated nucleoside (or 5'-side of the grown oligonucleotide chain).

10 **Gap regions with stereodefined phosphorothioate linkages**

As reported in Wan *et al.*, there is little benefit in introducing fully Rp or fully Sp gap regions in a gapmer, as compared to a random racemic mixture of phosphorothioate linkages. The present invention is based upon the surprising benefit that the introduction of at least one stereodefined phosphorothioate linkage may substantially improve the biological properties 15 of an oligonucleotide, e.g. see under advantages. This may be achieved by either introducing one or a number, e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 stereodefined phosphorothioate linkages, or by stereo specifying all the phosphorothioate linkages in the gap region.

In some embodiments, only 1, 2, 3, 4 or 5 of the internucleoside linkages of the central 20 region (Y') are stereoselective phosphorothioate linkages, and the remaining internucleoside linkages are randomly Rp or Sp.

In some embodiments, all of the internucleoside linkages of the central region (Y') are stereoselective phosphorothioate linkages.

In some embodiments, the central region (Y') comprises at least 5 contiguous 25 phosphorothioate linked DNA nucleoside. In some embodiments, the central region is at least 8 or 9 DNA nucleosides in length. In some embodiments, the central region is at least 10 or 11 DNA nucleosides in length. In some embodiments, the central region is at least 12 or 13 DNA nucleosides in length. In some embodiments, the central region is at least 14 or 15 DNA nucleosides in length.

30 **Stereo-Selective DNA Motifs**

We have previously identified that certain DNA dinucleotides may contribute to the toxicity profile of antisense oligonucleotides (Hagedorn *et al.*, Nucleic Acid Therapeutics 2013, 23; 302 – 310). In some embodiments of the invention, the toxicity of the DNA dinucleotides in antisense oligonucleotides, such as the LNA gapmer oligonucleotides described herein, may

be modulated via introducing stereoselective phosphorothioate internucleoside linkages between the DNA nucleosides of DNA dinucleotides, particularly dinucleotides which are known to contribute to toxicity, e.g. hepatotoxicity. In some embodiments the oligonucleotide of the invention comprises a DNA dinucleotide motif selected from the group 5 consisting of cc, tg, tc, ac, tt, gt, ca and gc, wherein the internucleoside linkage between the DNA nucleosides of the dinucleotide is a stereodefined phosphorothioate linkage such as either a Sp or a Rp phosphorothioate internucleoside linkage. Typically such dinucleotides may be within the gap region of a gapmer oligonucleotide, such as a LNA gapmer oligonucleotide. In some embodiments the oligonucleotide of the invention comprises at 10 least 2, such as at least 3 dinucleotides dependently or independently selected from the above list of DNA dinucleotide motifs.

#### ***RNAse recruitment***

It is recognised that an oligomeric compound may function via non RNase mediated degradation of target mRNA, such as by steric hindrance of translation, or other methods, In 15 some embodiments, the oligomers of the invention are capable of recruiting an endoribonuclease (RNase), such as RNase H.

It is preferable such oligomers, comprise a contiguous nucleotide sequence (region Y'), comprises of a region of at least 6, such as at least 7 consecutive nucleotide units, such as at least 8 or at least 9 consecutive nucleotide units (residues), including 7, 8, 9, 10, 11, 20 12, 13, 14, 15 or 16 consecutive nucleotides, which, when formed in a duplex with the complementary target RNA is capable of recruiting RNase. The contiguous sequence which is capable of recruiting RNase may be region Y' as referred to in the context of a gapmer as described herein. In some embodiments the size of the contiguous sequence which is capable of recruiting RNase, such as region Y', may be higher, such as 10, 11, 12, 13, 14, 25 15, 16, 17, 18, 19 or 20 nucleotide units.

EP 1 222 309 provides *in vitro* methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH. A oligomer is deemed capable of recruiting RNase H if, when provided with the complementary RNA target, it has an initial rate, as measured in pmol/l/min, of at least 1 %, such as at least 5%, such as at least 10% 30 or ,more than 20% of the of the initial rate determined using DNA only oligonucleotide, having the same base sequence but containing only DNA monomers, with no 2' substitutions, with phosphorothioate linkage groups between all monomers in the oligonucleotide, using the methodology provided by Example 91 - 95 of EP 1 222 309.

In some embodiments, an oligomer is deemed essentially incapable of recruiting RNaseH if, when provided with the complementary RNA target, and RNaseH, the RNaseH initial rate, as measured in pmol/l/min, is less than 1%, such as less than 5%, such as less than 10% or less than 20% of the initial rate determined using the equivalent DNA only 5 oligonucleotide, with no 2' substitutions, with phosphorothioate linkage groups between all nucleotides in the oligonucleotide, using the methodology provided by Example 91 - 95 of EP 1 222 309.

In other embodiments, an oligomer is deemed capable of recruiting RNaseH if, when provided with the complementary RNA target, and RNaseH, the RNaseH initial rate, as 10 measured in pmol/l/min, is at least 20%, such as at least 40 %, such as at least 60 %, such as at least 80 % of the initial rate determined using the equivalent DNA only oligonucleotide, with no 2' substitutions, with phosphorothioate linkage groups between all nucleotides in the oligonucleotide, using the methodology provided by Example 91 - 95 of EP 1 222 309.

Typically the region of the oligomer which forms the consecutive nucleotide units 15 which, when formed in a duplex with the complementary target RNA is capable of recruiting RNase consists of nucleotide units which form a DNA/RNA like duplex with the RNA target. The oligomer of the invention, such as the first region, may comprise a nucleotide sequence which comprises both nucleotides and nucleotide analogues, and may be e.g. in the form of a gapmer, a headmer or a tailmer.

20 A "headmer" is defined as an oligomer that comprises a region X' and a region Y' that is contiguous thereto, with the 5'-most monomer of region Y' linked to the 3'-most monomer of region X'. Region X' comprises a contiguous stretch of non-RNase recruiting nucleoside analogues and region Y' comprises a contiguous stretch (such as at least 7 contiguous monomers) of DNA monomers or nucleoside analogue monomers recognizable and 25 cleavable by the RNase.

20 A "tailmer" is defined as an oligomer that comprises a region X' and a region Y' that is contiguous thereto, with the 5'-most monomer of region Y linked to the 3'-most monomer of the region X'. Region X' comprises a contiguous stretch (such as at least 7 contiguous monomers) of DNA monomers or nucleoside analogue monomers recognizable and 30 cleavable by the RNase, and region X' comprises a contiguous stretch of non-RNase recruiting nucleoside analogues.

In some embodiments, in addition to enhancing affinity of the oligomer for the target region, some nucleoside analogues also mediate RNase (e.g., RNaseH) binding and 35 cleavage. Since  $\alpha$ -L-LNA (BNA) monomers recruit RNaseH activity to a certain extent, in some embodiments, gap regions (e.g., region Y' as referred to herein) of oligomers

containing  $\alpha$ -L-LNA monomers consist of fewer monomers recognizable and cleavable by the RNaseH, and more flexibility in the mixmer construction is introduced.

### ***Gapmer Design***

In some embodiments, the oligomer of the invention, comprises or is a LNA gapmer. A gapmer oligomer is an oligomer which comprises a contiguous stretch of nucleotides which is capable of recruiting an RNase, such as RNaseH, such as a region of at least 5, 6 or 7 DNA nucleotides, referred to herein in as region Y' (Y'), wherein region Y' is flanked both 5' and 3' by regions of affinity enhancing nucleotide analogues, such as from 1 – 6 affinity enhancing nucleotide analogues 5' and 3' to the contiguous stretch of nucleotides which is capable of recruiting RNase – these regions are referred to as regions X' (X') and Z' (Z') respectively. Examples of gapmers are disclosed in WO2004/046160, WO2008/113832, and WO2007/146511. The LNA gapmer oligomers of the invention comprise at least one LNA nucleoside in region X' or Z', such as at least one LNA nucleoside in region X' and at least one LNA nucleotide in region Z'.

In some embodiments, the monomers which are capable of recruiting RNase are selected from the group consisting of DNA monomers, alpha-L-LNA monomers, C4' alkylated DNA monomers (see PCT/EP2009/050349 and Vester *et al.*, *Bioorg. Med. Chem. Lett.* 18 (2008) 2296 – 2300, hereby incorporated by reference), and UNA (unlinked nucleic acid) nucleotides (see Fluiter *et al.*, *Mol. Biosyst.*, 2009, 10, 1039 hereby incorporated by reference). UNA is unlocked nucleic acid, typically where the C2 – C3 C-C bond of the ribose has been removed, forming an unlocked “sugar” residue. Preferably the gapmer comprises a (poly)nucleotide sequence of formula (5' to 3'), X'-Y'-Z', wherein; region X' (X') (5' region) consists or comprises of at least one high affinity nucleotide analogue, such as at least one LNA unit, such as from 1-6 affinity enhancing nucleotide analogues, such as LNA units, and; region Y' (Y') consists or comprises of at least five consecutive nucleotides which are capable of recruiting RNase (when formed in a duplex with a complementary RNA molecule, such as the mRNA target), such as DNA nucleotides, and; region Z' (Z') (3' region) consists or comprises of at least one high affinity nucleotide analogue, such as at least one LNA unit, such as from 1-6 affinity enhancing nucleotide analogues, such as LNA units.

In some embodiments, region X' comprises or consists of 1, 2, 3, 4, 5 or 6 LNA units, such as 2-5 LNA units, such as 3 or 4 LNA units,; and/or region Z' consists or comprises of 1, 2, 3, 4, 5 or 6 LNA units, such as from 2-5 LNA units, such as 3 or 4 LNA units.

In some embodiments, region X' may comprises of 1, 2, 3, 4, 5 or 6 2' substituted nucleotide analogues, such as 2'MOE; and/or region Z' comprises of 1, 2, 3, 4, 5 or 6 2'substituted nucleotide analogues, such as 2'MOE units.

In some embodiments, the substituent at the 2' position is selected from the group consisting of F; CF<sub>3</sub>, CN, N<sub>3</sub>, NO, NO<sub>2</sub>, O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, O-alkyl-N-alkyl or N-alkyl-O-alkyl wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkyl or C<sub>2</sub>-C<sub>10</sub> alkenyl and alkynyl. Examples of 2'

5 substituents include, and are not limited to, O(CH<sub>2</sub>) OCH<sub>3</sub>, and O(CH<sub>2</sub>) NH<sub>2</sub>, wherein n is from 1 to about 10, e.g. MOE, DMAOE, DMAEOE.

In some embodiments Y' consists or comprises of 5, 6, 7, 8, 9, 10, 11 or 12 consecutive nucleotides which are capable of recruiting RNase, or from 6-10, or from 7-9, such as 8 consecutive nucleotides which are capable of recruiting RNase. In some 10 embodiments region Y' consists or comprises at least one DNA nucleotide unit, such as 1-12 DNA units, preferably from 4-12 DNA units, more preferably from 6-10 DNA units, such as from 7-10 DNA units, such as 8, 9 or 10 DNA units.

In some embodiments region X' consist of 3 or 4 nucleotide analogues, such as LNA, region X' consists of 7, 8, 9 or 10 DNA units, and region Z' consists of 3 or 4 nucleotide 15 analogues, such as LNA. Such designs include (X'-Y'-Z') 3-10-3, 3-10-4, 4-10-3, 3-9-3, 3-9-4, 4-9-3, 3-8-3, 3-8-4, 4-8-3, 3-7-3, 3-7-4, 4-7-3.

Further gapmer designs are disclosed in WO2004/046160, which is hereby incorporated by reference. WO2008/113832, which claims priority from US provisional application 60/977,409 hereby incorporated by reference, refers to 'shortmer' gapmer 20 oligomers. In some embodiments, oligomers presented here may be such shortmer gapmers.

In some embodiments the oligomer, e.g. region X', is consisting of a contiguous nucleotide sequence of a total of 10, 11, 12, 13 or 14 nucleotide units, wherein the contiguous nucleotide sequence comprises or is of formula (5' – 3'), X'-Y'-Z' wherein; X' 25 consists of 1, 2 or 3 affinity enhancing nucleotide analogue units, such as LNA units; Y' consists of 7, 8 or 9 contiguous nucleotide units which are capable of recruiting RNase when formed in a duplex with a complementary RNA molecule (such as a mRNA target); and Z' consists of 1, 2 or 3 affinity enhancing nucleotide analogue units, such as LNA units.

In some embodiments the oligomer, comprises of a contiguous nucleotide sequence of 30 a total of 10, 11, 12, 13, 14, 15 or 16 nucleotide units, wherein the contiguous nucleotide sequence comprises or is of formula (5' – 3'), X'-Y'-Z' wherein; X' comprises of 1, 2, 3 or 4 LNA units; Y' consists of 7, 8, 9 or 10 contiguous nucleotide units which are capable of recruiting RNase when formed in a duplex with a complementary RNA molecule (such as a mRNA target) e.g. DNA nucleotides; and Z' comprises of 1, 2, 3 or 4 LNA units.

In some embodiments X' consists of 1 LNA unit. In some embodiments X' consists of 2 LNA units. In some embodiments X' consists of 3 LNA units. In some embodiments Z' consists of 1 LNA units. In some embodiments Z' consists of 2 LNA units. In some embodiments Z' consists of 3 LNA units. In some embodiments Y' consists of 7 nucleotide units. In some embodiments Y' consists of 8 nucleotide units. In some embodiments Y' consists of 9 nucleotide units. . In certain embodiments, region Y' consists of 10 nucleoside monomers. In certain embodiments, region Y' consists or comprises 1 – 10 DNA monomers. In some embodiments Y' comprises of from 1 – 9 DNA units, such as 2, 3, 4, 5, 6, 7, 8 or 9 DNA units. In some embodiments Y' consists of DNA units. In some embodiments Y' 5 comprises of at least one LNA unit which is in the alpha-L configuration, such as 2, 3, 4, 5, 6, 7, 8 or 9 LNA units in the alpha-L-configuration. In some embodiments Y' comprises of at 10 least one alpha-L-oxy LNA unit or wherein all the LNA units in the alpha-L- configuration are alpha-L-oxy LNA units. In some embodiments the number of nucleotides present in X'-Y'-Z' are selected from the group consisting of (nucleotide analogue units – region Y' – nucleotide 15 analogue units): 1-8-1, 1-8-2, 2-8-1, 2-8-2, 3-8-3, 2-8-3, 3-8-2, 4-8-1, 4-8-2, 1-8-4, 2-8-4, or; 1-9-1, 1-9-2, 2-9-1, 2-9-2, 2-9-3, 3-9-2, 1-9-3, 3-9-1, 4-9-1, 1-9-4, or; 1-10-1, 1-10-2, 2-10-1, 2-10-2, 1-10-3, 3-10-1. In some embodiments the number of nucleotides in X'-Y'-Z' are 20 selected from the group consisting of: 2-7-1, 1-7-2, 2-7-2, 3-7-3, 2-7-3, 3-7-2, 3-7-4, and 4-7-3. In certain embodiments, each of regions X' and Y' consists of three LNA monomers, and 25 region Y' consists of 8 or 9 or 10 nucleoside monomers, preferably DNA monomers. In some embodiments both X' and Z' consists of two LNA units each, and Y' consists of 8 or 9 nucleotide units, preferably DNA units. In various embodiments, other gapmer designs include those where regions X' and/or Z' consists of 3, 4, 5 or 6 nucleoside analogues, such as monomers containing a 2'-O-methoxyethyl-ribose sugar (2'-MOE) or monomers containing a 2'-fluoro-deoxyribose sugar, and region Y' consists of 8, 9, 10, 11 or 12 nucleosides, such as DNA monomers, where regions X'-Y'-Z' have 3-9-3, 3-10-3, 5-10-5 or 25 4-12-4 monomers. Further gapmer designs are disclosed in WO 2007/146511A2, hereby incorporated by reference.

30 In the gapmer designs reported herein the gap region (Y') may comprise one or more stereospecific phosphorothiote linkage, and the remaining internucleoside linkages of the gap region may e.g. be non-stereospecific internucleoside linkages, or may also be stereodefined phosphorothioate linkages. It is recognized that whilst the disruption of the gap region (G) with a beta-D-LNA, such as beta-D-oxy LNA or ScET nucleoside so that the 35 gap region does not comprise at least 5 consecutive DNA (or other RNaseH recruiting

nucleosides), usually interferes with RNaseH recruitment, in some embodiments, the disruption of the gap can result in retention of RNaseH recruitment. This is typically achieved by retention of at least 3 or 4 consecutive DNA nucleosides, and is typically sequence or even compound specific – see Rukov et al., NAR published online on July 28<sup>th</sup> 5 2015 which discloses “gap-breaker” oligonucleotides which recruit RNaseH which in some instances provide a more specific cleavage of the target RNA. Therefore in some embodiments region G may comprise a beta-D-oxy LNA nucleoside. In some embodiments the gap region G comprises an LNA nucleotide (e.g. beta-D-oxy, ScET or alpha-L-LNA) within the gap region so that the LNA nucleoside is flanked 5' or 3' by at least 3 (5') and 3 10 (3') or at least 3 (5') and 4 (3') or at least 4(5') and 3(3') DNA nucleosides, and wherein the oligonucleotide is capable of recruiting RNaseH.

### ***Internucleotide Linkages***

The oligomer of the invention comprises at least one stereodefined phosphorothioate linkage. Whilst the majority of compounds used for therapeutic use phosphorothioate 15 internucleotide linkages, it is possible to use other internucleoside linkages. However, in some embodiments all the internucleoside linkages of the oligomer of the invention are phosphorothioate internucleoside linkages. In some embodiments the linkages in the gap region are all phosphorothioate and the internucleoside linkages of the wing regions may be either phosphorothioate or phosphodiester linkages.

20 The nucleoside monomers of the oligomer described herein are coupled together via [internucleoside] linkage groups. Suitably, each monomer is linked to the 3' adjacent monomer via a linkage group.

The person having ordinary skill in the art would understand that, in the context of the 25 present invention, the 5' monomer at the end of an oligomer does not comprise a 5' linkage group, although it may or may not comprise a 5' terminal group.

The terms "linkage group" or "internucleotide linkage" are intended to mean a group capable of covalently coupling together two nucleotides. Specific and preferred examples include phosphate groups and phosphorothioate groups.

30 The nucleotides of the oligomer of the invention or contiguous nucleotides sequence thereof are coupled together via linkage groups. Suitably each nucleotide is linked to the 3' adjacent nucleotide via a linkage group.

Suitable internucleotide linkages include those listed within WO2007/031091, for example the internucleotide linkages listed on the first paragraph of page 34 of WO2007/031091 (hereby incorporated by reference).

It is, in some embodiments, desirable to modify the internucleotide linkage from its normal phosphodiester to one that is more resistant to nuclease attack, such as phosphorothioate or boranophosphate – these two, being cleavable by RNase H, also allow that route of antisense inhibition in reducing the expression of the target gene.

5 Suitable sulphur (S) containing internucleotide linkages as provided herein may be preferred, such as phosphorothioate or phosphodithioate. .

For gapmers, the internucleotide linkages in the oligomer may, for example be phosphorothioate or boranophosphate so as to allow RNase H cleavage of targeted RNA. Phosphorothioate is usually preferred, for improved nuclease resistance and other reasons, 10 such as ease of manufacture.

WO09124238 refers to oligomeric compounds having at least one bicyclic nucleoside (LNA) attached to the 3' or 5' termini by a neutral internucleoside linkage. The oligomers of the invention may therefore have at least one bicyclic nucleoside attached to the 3' or 5' termini by a neutral internucleoside linkage, such as one or more phosphotriester, 15 methylphosphonate, MMI, amide-3, formacetal or thioformacetal. The remaining linkages may be phosphorothioate.

### ***Nucleosides and Nucleoside analogues***

In some embodiments, the terms “nucleoside analogue” and “nucleotide analogue” are used interchangeably.

20 The term “nucleotide” as used herein, refers to a glycoside comprising a sugar moiety, a base moiety and a covalently linked group (linkage group), such as a phosphate or phosphorothioate internucleotide linkage group, and covers both naturally occurring nucleotides, such as DNA or RNA, and non-naturally occurring nucleotides comprising modified sugar and/or base moieties, which are also referred to as “nucleotide analogues” 25 herein. Herein, a single nucleotide (unit) may also be referred to as a monomer or nucleic acid unit.


In field of biochemistry, the term “nucleoside” is commonly used to refer to a glycoside comprising a sugar moiety and a base moiety, and may therefore be used when referring to the nucleotide units, which are covalently linked by the internucleotide linkages between the 30 nucleotides of the oligomer. In the field of biotechnology, the term “nucleotide” is often used to refer to a nucleic acid monomer or unit, and as such in the context of an oligonucleotide may refer to the base – such as the “nucleotide sequence”, typically refer to the nucleobase sequence (*i.e.* the presence of the sugar backbone and internucleoside linkages are implicit). Likewise, particularly in the case of oligonucleotides where one or more of the 35 internucleoside linkage groups are modified, the term “nucleotide” may refer to a

“nucleoside” for example the term “nucleotide” may be used, even when specifying the presence or nature of the linkages between the nucleosides.

As one of ordinary skill in the art would recognise, the 5' terminal nucleotide of an oligonucleotide does not comprise a 5' internucleotide linkage group, although may or may 5 not comprise a 5' terminal group.

Non-naturally occurring nucleotides include nucleotides which have modified sugar moieties, such as bicyclic nucleotides or 2' modified nucleotides, such as 2' substituted nucleotides.

“Nucleotide analogues” are variants of natural nucleotides, such as DNA or RNA 10 nucleotides, by virtue of modifications in the sugar and/or base moieties. Analogues could in principle be merely “silent” or “equivalent” to the natural nucleotides in the context of the oligonucleotide, *i.e.* have no functional effect on the way the oligonucleotide works to inhibit target gene expression. Such “equivalent” analogues may nevertheless be useful if, for example, they are easier or cheaper to manufacture, or are more stable to storage or 15 manufacturing conditions, or represent a tag or label. Preferably, however, the analogues will have a functional effect on the way in which the oligomer works to inhibit expression; for example by producing increased binding affinity to the target and/or increased resistance to intracellular nucleases and/or increased ease of transport into the cell. Specific examples of nucleoside analogues are described by *e.g.* Freier & Altmann; *Nucl. Acid Res.*, 1997, 25, 20 4429-4443 and Uhlmann; *Curr. Opinion in Drug Development*, 2000, 3(2), 293-213, and in Scheme 1:



Scheme 1

The oligomer may thus comprise or consist of a simple sequence of natural occurring

5 nucleotides – preferably 2'-deoxynucleotides (referred to here generally as “DNA”), but also possibly ribonucleotides (referred to here generally as “RNA”), or a combination of such naturally occurring nucleotides and one or more non-naturally occurring nucleotides, *i.e.* nucleotide analogues. Such nucleotide analogues may suitably enhance the affinity of the oligomer for the target sequence.

10 Examples of suitable and preferred nucleotide analogues are provided by WO2007/031091 or are referenced therein.

Incorporation of affinity-enhancing nucleotide analogues in the oligomer, such as LNA or 2'-substituted sugars, can allow the size of the specifically binding oligomer to be reduced, and may also reduce the upper limit to the size of the oligomer before non-specific 15 or aberrant binding takes place.

In some embodiments, the oligomer comprises at least 1 nucleotide analogue. In some embodiments the oligomer comprises at least 2 nucleotide analogues. In some embodiments, the oligomer comprises from 3-8 nucleotide analogues, *e.g.* 6 or 7 nucleotide

analogues. In the by far most preferred embodiments, at least one of said nucleotide analogues is a locked nucleic acid (LNA); for example at least 3 or at least 4, or at least 5, or at least 6, or at least 7, or 8, of the nucleotide analogues may be LNA. In some embodiments all the nucleotides analogues may be LNA.

5 It will be recognised that when referring to a preferred nucleotide sequence motif or nucleotide sequence, which consists of only nucleotides, the oligomers of the invention which are defined by that sequence may comprise a corresponding nucleotide analogue in place of one or more of the nucleotides present in said sequence, such as LNA units or other nucleotide analogues, which raise the duplex stability/T<sub>m</sub> of the oligomer/target duplex  
10 (i.e. affinity enhancing nucleotide analogues).

Examples of such modification of the nucleotide include modifying the sugar moiety to provide a 2'-substituent group or to produce a bridged (locked nucleic acid) structure which enhances binding affinity and may also provide increased nuclease resistance.

15 A preferred nucleotide analogue is LNA, such as oxy-LNA (such as beta-D-oxy-LNA, and alpha-L-oxy-LNA), and/or amino-LNA (such as beta-D-amino-LNA and alpha-L-amino-LNA) and/or thio-LNA (such as beta-D-thio-LNA and alpha-L-thio-LNA) and/or ENA (such as beta-D-ENA and alpha-L-ENA). Most preferred is beta-D-oxy-LNA.

20 In some embodiments the nucleotide analogues present within the oligomer of the invention (such as in regions X' and Y' mentioned herein) are independently selected from, for example: 2'-O-alkyl-RNA units, 2'-amino-DNA units, 2'-fluoro-DNA units, LNA units, arabino nucleic acid (ANA) units, 2'-fluoro-ANA units, HNA units, INA (intercalating nucleic acid -Christensen, 2002. Nucl. Acids. Res. 2002 30: 4918-4925, hereby incorporated by reference) units and 2'MOE units. In some embodiments there is only one of the above types of nucleotide analogues present in the oligomer of the invention, or contiguous  
25 nucleotide sequence thereof.

20 In some embodiments the nucleotide analogues are 2'-O-methoxyethyl-RNA (2'MOE), 2'-fluoro-DNA monomers or LNA nucleotide analogues, and as such the oligonucleotide of the invention may comprise nucleotide analogues which are independently selected from these three types of analogue, or may comprise only one type of analogue selected from the  
30 three types. In some embodiments at least one of said nucleotide analogues is 2'-MOE-RNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2'-MOE-RNA nucleotide units. In some embodiments at least one of said nucleotide analogues is 2'-fluoro DNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2'-fluoro-DNA nucleotide units.

35 In some embodiments, the oligomer according to the invention comprises at least one Locked Nucleic Acid (LNA) unit, such as 1, 2, 3, 4, 5, 6, 7, or 8 LNA units, such as from 3 –

7 or 4 to 8 LNA units, or 3, 4, 5, 6 or 7 LNA units. In some embodiments, all the nucleotide analogues are LNA. In some embodiments, the oligomer may comprise both beta-D-oxy-LNA, and one or more of the following LNA units: thio-LNA, amino-LNA, oxy-LNA, and/or ENA in either the beta-D or alpha-L configurations or combinations thereof. In some 5 embodiments all LNA cytosine units are 5'methyl-Cytosine. In some embodiments of the invention, the oligomer may comprise both LNA and DNA units. Preferably the combined total of LNA and DNA units is 10-25, such as 10 – 24, preferably 10-20, such as 10 – 18, even more preferably 12-16. In some embodiments of the invention, the nucleotide sequence of the oligomer, such as the contiguous nucleotide sequence consists of at least 10 one LNA and the remaining nucleotide units are DNA units. In some embodiments the oligomer comprises only LNA nucleotide analogues and naturally occurring nucleotides (such as RNA or DNA, most preferably DNA nucleotides), optionally with modified internucleotide linkages such as phosphorothioate.

The term “nucleobase” refers to the base moiety of a nucleotide and covers both 15 naturally occurring as well as non-naturally occurring variants. Thus, “nucleobase” covers not only the known purine and pyrimidine heterocycles but also heterocyclic analogues and tautomeres thereof.


Examples of nucleobases include, but are not limited to adenine, guanine, cytosine, thymidine, uracil, xanthine, hypoxanthine, 5-methylcytosine, isocytosine, pseudoisocytosine, 20 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, diaminopurine, and 2-chloro-6-aminopurine.

In some embodiments, at least one of the nucleobases present in the oligomer is a modified nucleobase selected from the group consisting of 5-methylcytosine, isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, 25 diaminopurine, and 2-chloro-6-aminopurine.

### **LNA**

The term “LNA” refers to a bicyclic nucleoside analogue, known as “Locked Nucleic Acid”. It may refer to an LNA monomer, or, when used in the context of an “LNA oligonucleotide”, LNA refers to an oligonucleotide containing one or more such bicyclic 30 nucleotide analogues. LNA nucleotides are characterised by the presence of a linker group (such as a bridge) between C2' and C4' of the ribose sugar ring – for example as shown as the biradical  $R^{4*} - R^{2*}$  as described below.

The LNA used in the oligonucleotide compounds of the invention preferably has the structure of the general formula I



wherein for all chiral centers, asymmetric groups may be found in either R or S

orientation;

wherein X is selected from -O-, -S-, -N(R<sup>N\*</sup>)-, -C(R<sup>6</sup>R<sup>6\*</sup>)-, such as, in some

5 embodiments -O-;

B is selected from hydrogen, optionally substituted C<sub>1-4</sub>-alkoxy, optionally substituted C<sub>1-4</sub>-alkyl, optionally substituted C<sub>1-4</sub>-acyloxy, nucleobases including naturally occurring and nucleobase analogues, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands; preferably, B is a nucleobase

10 or nucleobase analogue;

P designates an internucleotide linkage to an adjacent monomer, or a 5'-terminal group, such internucleotide linkage or 5'-terminal group optionally including the substituent R<sup>5</sup> or equally applicable the substituent R<sup>5\*</sup>;

P\* designates an internucleotide linkage to an adjacent monomer, or a 3'-terminal

15 group;

R<sup>4\*</sup> and R<sup>2\*</sup> together designate a bivalent linker group consisting of 1 - 4 groups/atoms selected from -C(R<sup>a</sup>R<sup>b</sup>)-, -C(R<sup>a</sup>)=C(R<sup>b</sup>)-, -C(R<sup>a</sup>)=N-, -O-, -Si(R<sup>a</sup>)<sub>2</sub>-, -S-, -SO<sub>2</sub>-, -N(R<sup>a</sup>)-, and >C=Z, wherein Z is selected from -O-, -S-, and -N(R<sup>a</sup>)-, and R<sup>a</sup> and R<sup>b</sup> each is independently selected from hydrogen, optionally substituted C<sub>1-12</sub>-alkyl, optionally substituted C<sub>2-12</sub>-alkenyl,

20 optionally substituted C<sub>2-12</sub>-alkynyl, hydroxy, optionally substituted C<sub>1-12</sub>-alkoxy, C<sub>2-12</sub>-alkoxyalkyl, C<sub>2-12</sub>-alkenyloxy, carboxy, C<sub>1-12</sub>-alkoxycarbonyl, C<sub>1-12</sub>-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C<sub>1-6</sub>-alkyl)amino, carbamoyl, mono- and di(C<sub>1-6</sub>-alkyl)-amino-carbonyl, amino-C<sub>1-6</sub>-alkyl-aminocarbonyl, mono- and di(C<sub>1-6</sub>-alkyl)amino-C<sub>1-6</sub>-alkyl-aminocarbonyl, C<sub>1-6</sub>-alkyl-carbonylamino, carbamido, C<sub>1-6</sub>-alkanoyloxy, sulphono, C<sub>1-6</sub>-alkylsulphonyloxy, nitro, azido, sulphanyl, C<sub>1-6</sub>-alkylthio, halogen, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter

groups, and ligands, where aryl and heteroaryl may be optionally substituted and where two geminal substituents R<sup>a</sup> and R<sup>b</sup> together may designate optionally substituted methylene (=CH<sub>2</sub>), wherein for all chiral centers, asymmetric groups may be found in either *R* or *S* orientation, and;

5 each of the substituents R<sup>1\*</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>5\*</sup>, R<sup>6</sup> and R<sup>6\*</sup>, which are present is independently selected from hydrogen, optionally substituted C<sub>1-12</sub>-alkyl, optionally substituted C<sub>2-12</sub>-alkenyl, optionally substituted C<sub>2-12</sub>-alkynyl, hydroxy, C<sub>1-12</sub>-alkoxy, C<sub>2-12</sub>-alkoxyalkyl, C<sub>2-12</sub>-alkenyloxy, carboxy, C<sub>1-12</sub>-alkoxycarbonyl, C<sub>1-12</sub>-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C<sub>1-6</sub>-alkyl)amino, carbamoyl, mono- and di(C<sub>1-6</sub>-alkyl)-amino-carbonyl, amino-C<sub>1-6</sub>-alkyl-aminocarbonyl, mono- and di(C<sub>1-6</sub>-alkyl)amino-C<sub>1-6</sub>-alkyl-aminocarbonyl, C<sub>1-6</sub>-alkyl-carbonylamino, carbamido, C<sub>1-6</sub>-alkanoyloxy, sulphono, C<sub>1-6</sub>-alkylsulphonyloxy, nitro, azido, sulphanyl, C<sub>1-6</sub>-alkylthio, halogen, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, where aryl and heteroaryl may be optionally substituted, and where two geminal substituents together may designate oxo, thioxo, imino, or optionally substituted methylene; ; wherein R<sup>N</sup> is selected from hydrogen and C<sub>1-4</sub>-alkyl, and where two adjacent (non-geminal) substituents may designate an additional bond resulting in a double bond; and R<sup>N\*</sup>, when present and not involved in a biradical, is selected from hydrogen and C<sub>1-4</sub>-alkyl;

10 and basic salts and acid addition salts thereof. For all chiral centers, asymmetric groups may be found in either *R* or *S* orientation.

15

20

In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate a biradical consisting of a groups selected from the group consisting of C(R<sup>a</sup>R<sup>b</sup>)-C(R<sup>a</sup>R<sup>b</sup>)-, C(R<sup>a</sup>R<sup>b</sup>)-O-, C(R<sup>a</sup>R<sup>b</sup>)-NR<sup>a</sup>-, C(R<sup>a</sup>R<sup>b</sup>)-S-, and C(R<sup>a</sup>R<sup>b</sup>)-C(R<sup>a</sup>R<sup>b</sup>)-O-, wherein each R<sup>a</sup> and R<sup>b</sup> may optionally be independently selected. In some embodiments, R<sup>a</sup> and R<sup>b</sup> may be, optionally independently selected from the group consisting of hydrogen and C<sub>1-6</sub>-alkyl, such as methyl, such as hydrogen.

25

30

In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate the biradical -O-CH(CH<sub>2</sub>OCH<sub>3</sub>)-(2'O-methoxyethyl bicyclic nucleic acid - Seth et al., 2010, J. Org. Chem) – in either the R- or S- configuration.


In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate the biradical -O-CH(CH<sub>2</sub>CH<sub>3</sub>)-(2'O-ethyl bicyclic nucleic acid - Seth et al., 2010, J. Org. Chem). – in either the R- or S- configuration.

In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate the biradical –O-CH(CH<sub>3</sub>)–. – in either the R- or S- configuration. In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate the biradical –O-CH<sub>2</sub>-O-CH<sub>2</sub>– (Seth et al., 2010, J. Org. Chem.).

In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate the biradical –O-NR-CH<sub>3</sub>– –

5 (Seth et al., 2010, J. Org. Chem.).

In some embodiments, the LNA units have a structure selected from the following group:



10

In some embodiments, R<sup>1\*</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>5\*</sup> are independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl or substituted C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkoxy, substituted C<sub>1-6</sub> alkoxy, acyl, substituted acyl, C<sub>1-6</sub> aminoalkyl or substituted C<sub>1-6</sub> aminoalkyl. For all chiral centers, asymmetric groups may be found in either R or S orientation.

15 In some embodiments, R<sup>1\*</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>5\*</sup> are hydrogen.

In some embodiments, R<sup>1\*</sup>, R<sup>2</sup>, R<sup>3</sup> are independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl or substituted C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkoxy, substituted C<sub>1-6</sub> alkoxy, acyl, substituted acyl, C<sub>1-6</sub> aminoalkyl or substituted C<sub>1-6</sub> aminoalkyl. For all chiral centers, asymmetric groups may be found in either R or S orientation.

20 In some embodiments, R<sup>1\*</sup>, R<sup>2</sup>, R<sup>3</sup> are hydrogen.

25 In some embodiments, R<sup>5</sup> and R<sup>5\*</sup> are each independently selected from the group consisting of H, –CH<sub>3</sub>, -CH<sub>2</sub>-CH<sub>3</sub>, -CH<sub>2</sub>-O-CH<sub>3</sub>, and -CH=CH<sub>2</sub>. Suitably in some embodiments, either R<sup>5</sup> or R<sup>5\*</sup> are hydrogen, where as the other group (R<sup>5</sup> or R<sup>5\*</sup> respectively) is selected from the group consisting of C<sub>1-5</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, substituted C<sub>1-6</sub> alkyl, substituted C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkynyl or substituted acyl (-C(=O)-); wherein each substituted group is mono or poly substituted with substituent groups independently selected from halogen, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, substituted C<sub>2-6</sub> alkynyl, OJ<sub>1</sub>, SJ<sub>1</sub>, NJ<sub>1</sub>J<sub>2</sub>, N<sub>3</sub>, COOJ<sub>1</sub>, CN, O-C(=O)NJ<sub>1</sub>J<sub>2</sub>, N(H)C(=NH)NJ<sub>1</sub>J<sub>2</sub> or N(H)C(=X)N(H)J<sub>2</sub> wherein X is O or S; and each J<sub>1</sub> and

J<sub>2</sub> is, independently, H, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, substituted C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> aminoalkyl, substituted C<sub>1-6</sub> aminoalkyl or a protecting group. In some embodiments either R<sup>5</sup> or R<sup>5\*</sup> is substituted C<sub>1-6</sub> alkyl. In some embodiments either R<sup>5</sup> or R<sup>5\*</sup> is substituted methylene wherein preferred substituent groups 5 include one or more groups independently selected from F, NJ<sub>1</sub>J<sub>2</sub>, N<sub>3</sub>, CN, OJ<sub>1</sub>, SJ<sub>1</sub>, O-C(=O)NJ<sub>1</sub>J<sub>2</sub>, N(H)C(=NH)NJ, J<sub>2</sub> or N(H)C(O)N(H)J<sub>2</sub>. In some embodiments each J<sub>1</sub> and J<sub>2</sub> is, independently H or C<sub>1-6</sub> alkyl. In some embodiments either R<sup>5</sup> or R<sup>5\*</sup> is methyl, ethyl or methoxymethyl. In some embodiments either R<sup>5</sup> or R<sup>5\*</sup> is methyl. In a further embodiment 10 either R<sup>5</sup> or R<sup>5\*</sup> is ethylenyl. In some embodiments either R<sup>5</sup> or R<sup>5\*</sup> is substituted acyl. In some embodiments either R<sup>5</sup> or R<sup>5\*</sup> is C(=O)NJ<sub>1</sub>J<sub>2</sub>. For all chiral centers, asymmetric groups 15 may be found in either R or S orientation. Such 5' modified bicyclic nucleotides are disclosed in WO 2007/134181, which is hereby incorporated by reference in its entirety.

In some embodiments B is a nucleobase, including nucleobase analogues and naturally occurring nucleobases, such as a purine or pyrimidine, or a substituted purine or 15 substituted pyrimidine, such as a nucleobase referred to herein, such as a nucleobase selected from the group consisting of adenine, cytosine, thymine, adenine, uracil, and/or a modified or substituted nucleobase, such as 5-thiazolo-uracil, 2-thio-uracil, 5-propynyl-uracil, 2'thio-thymine, 5-methyl cytosine, 5-thiazolo-cytosine, 5-propynyl-cytosine, and 2,6-diaminopurine.

20 In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate a biradical selected from - C(R<sup>a</sup>R<sup>b</sup>)-O-, -C(R<sup>a</sup>R<sup>b</sup>)-C(R<sup>c</sup>R<sup>d</sup>)-O-, -C(R<sup>a</sup>R<sup>b</sup>)-C(R<sup>c</sup>R<sup>d</sup>)-C(R<sup>e</sup>R<sup>f</sup>)-O-, -C(R<sup>a</sup>R<sup>b</sup>)-O-C(R<sup>c</sup>R<sup>d</sup>)-, -C(R<sup>a</sup>R<sup>b</sup>)-O-C(R<sup>c</sup>R<sup>d</sup>)-C(R<sup>e</sup>R<sup>f</sup>)-, -C(R<sup>a</sup>)=C(R<sup>b</sup>)-C(R<sup>c</sup>R<sup>d</sup>)-, -C(R<sup>a</sup>R<sup>b</sup>)-N(R<sup>c</sup>)-, -C(R<sup>a</sup>R<sup>b</sup>)-C(R<sup>c</sup>R<sup>d</sup>)-N(R<sup>e</sup>)-, -C(R<sup>a</sup>R<sup>b</sup>)-N(R<sup>c</sup>)-O-, and -C(R<sup>a</sup>R<sup>b</sup>)-S-, -C(R<sup>a</sup>R<sup>b</sup>)-C(R<sup>c</sup>R<sup>d</sup>)-S-, wherein R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>e</sup>, and R<sup>f</sup> each is independently 25 selected from hydrogen, optionally substituted C<sub>1-12</sub>-alkyl, optionally substituted C<sub>2-12</sub>-alkenyl, optionally substituted C<sub>2-12</sub>-alkynyl, hydroxy, C<sub>1-12</sub>-alkoxy, C<sub>2-12</sub>-alkoxylalkyl, C<sub>2-12</sub>-alkenylloxy, carboxy, C<sub>1-12</sub>-alkoxycarbonyl, C<sub>1-12</sub>-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C<sub>1-6</sub>-alkyl)amino, carbamoyl, mono- and di(C<sub>1-6</sub>-alkyl)-amino-carbonyl, amino-30 C<sub>1-6</sub>-alkyl-aminocarbonyl, mono- and di(C<sub>1-6</sub>-alkyl)amino-C<sub>1-6</sub>-alkyl-aminocarbonyl, C<sub>1-6</sub>-alkyl-carbonylamino, carbamido, C<sub>1-6</sub>-alkanoyloxy, sulphono, C<sub>1-6</sub>-alkylsulphonyloxy, nitro, azido, sulphanyl, C<sub>1-6</sub>-alkylthio, halogen, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, where aryl and heteroaryl may be optionally substituted and where two geminal substituents R<sup>a</sup> and R<sup>b</sup>

together may designate optionally substituted methylene (=CH<sub>2</sub>). For all chiral centers, asymmetric groups may be found in either *R* or *S* orientation.

In a further embodiment R<sup>4\*</sup> and R<sup>2\*</sup> together designate a biradical (bivalent group) selected from -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-, -CH<sub>2</sub>-CH<sub>2</sub>-O-, -CH<sub>2</sub>-CH(CH<sub>3</sub>)-, -CH<sub>2</sub>-CH<sub>2</sub>-S-, -CH<sub>2</sub>-CH<sub>2</sub>-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-O-, -CH<sub>2</sub>-CH<sub>2</sub>-CH(CH<sub>3</sub>)-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-O-CH<sub>2</sub>-O-, -CH<sub>2</sub>-NH-O-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-O-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH(CH<sub>3</sub>)-O-, and -CH(CH<sub>2</sub>-O-CH<sub>3</sub>)-O-, and/or, -CH<sub>2</sub>-CH<sub>2</sub>-, and -CH=CH- For all chiral centers, asymmetric groups may be found in either *R* or *S* orientation.

In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate the biradical C(R<sup>a</sup>R<sup>b</sup>)-N(R<sup>c</sup>)-O-, wherein R<sup>a</sup> and R<sup>b</sup> are independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl or substituted C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkoxy, substituted C<sub>1-6</sub> alkoxy, acyl, substituted acyl, C<sub>1-6</sub> aminoalkyl or substituted C<sub>1-6</sub> aminoalkyl, such as hydrogen, and; wherein R<sup>c</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl or substituted C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkoxy, substituted C<sub>1-6</sub> alkoxy, acyl, substituted acyl, C<sub>1-6</sub> aminoalkyl or substituted C<sub>1-6</sub> aminoalkyl, such as hydrogen.

In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> together designate the biradical C(R<sup>a</sup>R<sup>b</sup>)-O-C(R<sup>c</sup>R<sup>d</sup>)-O-, wherein R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup>, and R<sup>d</sup> are independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl or substituted C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkoxy, substituted C<sub>1-6</sub> alkoxy, acyl, substituted acyl, C<sub>1-6</sub> aminoalkyl or substituted C<sub>1-6</sub> aminoalkyl, such as hydrogen.

In some embodiments, R<sup>4\*</sup> and R<sup>2\*</sup> form the biradical -CH(Z)-O-, wherein Z is selected from the group consisting of C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, substituted C<sub>1-6</sub> alkyl, substituted C<sub>2-6</sub> alkenyl, substituted C<sub>2-6</sub> alkynyl, acyl, substituted acyl, substituted amide, thiol or substituted thio; and wherein each of the substituted groups, is, independently, mono or poly substituted with optionally protected substituent groups independently selected from halogen, oxo, hydroxyl, OJ<sub>1</sub>, NJ<sub>1</sub>J<sub>2</sub>, SJ<sub>1</sub>, N<sub>3</sub>, OC(=X)J<sub>1</sub>, OC(=X)NJ<sub>1</sub>J<sub>2</sub>, NJ<sup>3</sup>C(=X)NJ<sub>1</sub>J<sub>2</sub> and CN, wherein each J<sub>1</sub>, J<sub>2</sub> and J<sub>3</sub> is, independently, H or C<sub>1-6</sub> alkyl, and X is O, S or NJ<sub>1</sub>. In some embodiments Z is C<sub>1-6</sub> alkyl or substituted C<sub>1-6</sub> alkyl. In some embodiments Z is methyl. In some embodiments Z is substituted C<sub>1-6</sub> alkyl. In some embodiments said substituent group is C<sub>1-6</sub> alkoxy. In some embodiments Z is CH<sub>3</sub>OCH<sub>2</sub>- For all chiral centers, asymmetric groups may be found in either *R* or *S* orientation. Such bicyclic nucleotides are disclosed in US 7,399,845 which is hereby incorporated by reference in its entirety. In some

embodiments,  $R^{1*}$ ,  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^{5*}$  are hydrogen. In some some embodiments,  $R^{1*}$ ,  $R^2$ ,  $R^3$  are hydrogen, and one or both of  $R^5$ ,  $R^{5*}$  may be other than hydrogen as referred to above and in WO 2007/134181.


In some embodiments,  $R^{4*}$  and  $R^{2*}$  together designate a biradical which comprise a substituted amino group in the bridge such as consist or comprise of the biradical  $-\text{CH}_2\text{N}(R^c)-$ , wherein  $R^c$  is  $C_{1-12}$  alkyloxy. In some embodiments  $R^{4*}$  and  $R^{2*}$  together designate a biradical  $-\text{Cq}_3\text{q}_4\text{-NOR}-$ , wherein  $q_3$  and  $q_4$  are independently selected from the group consisting of hydrogen, halogen,  $C_{1-6}$  alkyl, substituted  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, substituted  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl or substituted  $C_{2-6}$  alkynyl,  $C_{1-6}$  alkoxy, substituted  $C_{1-6}$  alkoxy, acyl, substituted acyl,  $C_{1-6}$  aminoalkyl or substituted  $C_{1-6}$  aminoalkyl; wherein each substituted group is, independently, mono or poly substituted with substituent groups independently selected from halogen,  $OJ_1$ ,  $SJ_1$ ,  $NJ_1J_2$ ,  $\text{COOJ}_1$ ,  $CN$ ,  $O\text{-C}(=O)\text{NJ}_1J_2$ ,  $N(H)\text{C}(=\text{NH})\text{N J}_1J_2$  or  $N(H)\text{C}(=X=N(H)J_2$  wherein  $X$  is  $O$  or  $S$ ; and each of  $J_1$  and  $J_2$  is, independently,  $H$ ,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  aminoalkyl or a protecting group. For all chiral centers, asymmetric groups may be found in either *R* or *S* orientation. Such bicyclic nucleotides are disclosed in WO2008/150729 which is hereby incorporated by reference in its entirety. In some embodiments,  $R^{1*}$ ,  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^{5*}$  are independently selected from the group consisting of hydrogen, halogen,  $C_{1-6}$  alkyl, substituted  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, substituted  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl or substituted  $C_{2-6}$  alkynyl,  $C_{1-6}$  alkoxy, substituted  $C_{1-6}$  alkoxy, acyl, substituted acyl,  $C_{1-6}$  aminoalkyl or substituted  $C_{1-6}$  aminoalkyl. In some embodiments,  $R^{1*}$ ,  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^{5*}$  are hydrogen. In some embodiments,  $R^{1*}$ ,  $R^2$ ,  $R^3$  are hydrogen and one or both of  $R^5$ ,  $R^{5*}$  may be other than hydrogen as referred to above and in WO 2007/134181. In some embodiments  $R^{4*}$  and  $R^{2*}$  together designate a biradical (bivalent group)  $C(R^aR^b)\text{-O-}$ , wherein  $R^a$  and  $R^b$  are each independently halogen,  $C_{1-C_{12}}$  alkyl, substituted  $C_{1-C_{12}}$  alkyl,  $C_{2-C_{12}}$  alkenyl, substituted  $C_{2-C_{12}}$  alkenyl,  $C_{2-C_{12}}$  alkynyl, substituted  $C_{2-C_{12}}$  alkynyl,  $C_{1-C_{12}}$  alkoxy, substituted  $C_{1-C_{12}}$  alkoxy,  $OJ_1$   $SJ_1$ ,  $SOJ_1$ ,  $SO_2J_1$ ,  $NJ_1J_2$ ,  $N_3$ ,  $CN$ ,  $C(=O)OJ_1$ ,  $C(=O)\text{NJ}_1J_2$ ,  $C(=O)J_1$ ,  $O\text{-C}(=O)\text{NJ}_1J_2$ ,  $N(H)\text{C}(=\text{NH})\text{NJ}_1J_2$ ,  $N(H)\text{C}(=O)\text{NJ}_1J_2$  or  $N(H)\text{C}(=S)\text{NJ}_1J_2$ ; or  $R^a$  and  $R^b$  together are  $=C(q_3)(q_4)$ ;  $q_3$  and  $q_4$  are each, independently,  $H$ , halogen,  $C_{1-C_{12}}$  alkyl or substituted  $C_{1-C_{12}}$  alkyl; each substituted group is, independently, mono or poly substituted with substituent groups independently selected from halogen,  $C_{1-C_6}$  alkyl, substituted  $C_{1-C_6}$  alkyl,  $C_{2-C_6}$  alkenyl, substituted  $C_{2-C_6}$  alkenyl,  $C_{2-C_6}$  alkynyl, substituted  $C_{2-C_6}$  alkynyl,  $OJ_1$ ,  $SJ_1$ ,  $NJ_1J_2$ ,  $N_3$ ,  $CN$ ,  $C(=O)OJ_1$ ,  $C(=O)\text{NJ}_1J_2$ ,  $C(=O)J_1$ ,  $O\text{-C}(=O)\text{NJ}_1J_2$ ,  $N(H)\text{C}(=O)\text{NJ}_1J_2$  or  $N(H)\text{C}(=S)\text{NJ}_1J_2$  and; each  $J_1$  and  $J_2$  is, independently,  $H$ ,  $C_{1-C_6}$  alkyl, substituted  $C_{1-C_6}$  alkyl,  $C_{2-C_6}$  alkenyl, substituted  $C_{2-C_6}$  alkenyl,  $C_{2-C_6}$  alkynyl, substituted  $C_{2-C_6}$  alkynyl,  $C_{1-C_6}$  aminoalkyl, substituted  $C_{1-C_6}$  aminoalkyl or a protecting

group. Such compounds are disclosed in WO2009006478A, hereby incorporated in its entirety by reference.

In some embodiments,  $R^{4*}$  and  $R^{2*}$  form the biradical - Q -, wherein Q is  $C(q_1)(q_2)C(q_3)(q_4)$ ,  $C(q_1)=C(q_3)$ ,  $C[=C(q_1)(q_2)]-C(q_3)(q_4)$  or  $C(q_1)(q_2)-C[=C(q_3)(q_4)]$ ;  $q_1$ ,  $q_2$ ,  $q_3$ ,  $q_4$  are each independently H, halogen,  $C_{1-12}$  alkyl, substituted  $C_{1-12}$  alkyl,  $C_{2-12}$  alkenyl, substituted  $C_{1-12}$  alkoxy,  $OJ_1$ ,  $SJ_1$ ,  $SO_2J_1$ ,  $NJ_1J_2$ ,  $N_3$ ,  $CN$ ,  $C(=O)OJ_1$ ,  $C(=O)-NJ_1J_2$ ,  $C(=O)J_1$ ,  $-C(=O)NJ_1J_2$ ,  $N(H)C(=NH)NJ_1J_2$ ,  $N(H)C(=O)NJ_1J_2$  or  $N(H)C(=S)NJ_1J_2$ ; each  $J_1$  and  $J_2$  is, independently, H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  aminoalkyl or a protecting group; and, optionally wherein when Q is  $C(q_1)(q_2)(q_3)(q_4)$  and one of  $q_3$  or  $q_4$  is  $CH_3$  then at least one of the other of  $q_3$  or  $q_4$  or one of  $q_1$  and  $q_2$  is other than H. In some embodiments,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^{5*}$  are hydrogen. For all chiral centers, asymmetric groups may be found in either R or S orientation. Such bicyclic nucleotides are disclosed in WO2008/154401 which is hereby incorporated by reference in its entirety. In some embodiments,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^{5*}$  are independently selected from the group consisting of hydrogen, halogen,  $C_{1-6}$  alkyl, substituted  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, substituted  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl or substituted  $C_{2-6}$  alkynyl,  $C_{1-6}$  alkoxy, substituted  $C_{1-6}$  alkoxy, acyl, substituted acyl,  $C_{1-6}$  aminoalkyl or substituted  $C_{1-6}$  aminoalkyl. In some embodiments,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^{5*}$  are hydrogen. In some embodiments,  $R^1$ ,  $R^2$ ,  $R^3$  are hydrogen and one or both of  $R^5$ ,  $R^{5*}$  may be other than hydrogen as referred to above and in WO 2007/134181 or WO2009/067647 (alpha-L-bicyclic nucleic acids analogs).



Further bicyclic nucleoside analogues and their use in antisense oligonucleotides are disclosed in WO2011/115818, WO2011/085102, WO2011/017521, WO2009100320, WO10036698, WO20124295 & WO2009006478. Such nucleoside analogues may in some aspects be useful in the compounds of present invention.

In some embodiments the LNA used in the oligonucleotide compounds of the invention preferably has the structure of the general formula II:





wherein Y is selected from the group consisting of  $-O-$ ,  $-CH_2O-$ ,  $-S-$ ,  $-NH-$ ,  $N(R^e)$  and/or  $-CH_2-$ ; Z and  $Z^*$  are independently selected among an internucleotide linkage,  $R^H$ , a terminal




group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety (nucleobase), and  $R^H$  is selected from hydrogen and  $C_{1-4}$ -alkyl;  $R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$  and  $R^e$  are, optionally independently, selected from the group consisting of hydrogen, optionally substituted  $C_{1-12}$ -alkyl, optionally substituted  $C_{2-12}$ -alkenyl, optionally substituted  $C_{2-12}$ -alkynyl, 5 hydroxy,  $C_{1-12}$ -alkoxy,  $C_{2-12}$ -alkoxyalkyl,  $C_{2-12}$ -alkenyloxy, carboxy,  $C_{1-12}$ -alkoxycarbonyl,  $C_{1-12}$ -alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di( $C_{1-6}$ -alkyl)amino, carbamoyl, mono- and di( $C_{1-6}$ -alkyl)-amino-carbonyl, amino- $C_{1-6}$ -alkyl-aminocarbonyl, mono- and di( $C_{1-6}$ -alkyl)amino- $C_{1-6}$ -alkyl-aminocarbonyl,  $C_{1-6}$ -alkyl-carbonylamino, carbamido,  $C_{1-6}$ -alkanoyloxy, sulphono,  $C_{1-6}$ -alkylsulphonyloxy, nitro, azido, sulphanyl,  $C_{1-6}$ -alkylthio, halogen, 10 DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, where aryl and heteroaryl may be optionally substituted and where two geminal substituents  $R^a$  and  $R^b$  together may designate optionally substituted methylene ( $=CH_2$ ); and  $R^H$  is selected from hydrogen and  $C_{1-4}$ -alkyl. In some 15 embodiments  $R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$  and  $R^e$  are, optionally independently, selected from the group consisting of hydrogen and  $C_{1-6}$  alkyl, such as methyl. For all chiral centers, asymmetric groups may be found in either R or S orientation, for example, two exemplary stereochemical isomers include the beta-D and alpha-L isoforms, which may be illustrated as follows:



20

Specific exemplary LNA units are shown below:



 $\beta$ -D-thio-LNA $\beta$ -D-ENA $\beta$ -D-amino-LNA

The term "thio-LNA" comprises a locked nucleotide in which Y in the general formula above is selected from S or  $-\text{CH}_2\text{-S-}$ . Thio-LNA can be in both beta-D and alpha-L-configuration.

The term "amino-LNA" comprises a locked nucleotide in which Y in the general

5 formula above is selected from  $-\text{N}(\text{H})-$ ,  $\text{N}(\text{R})-$ ,  $\text{CH}_2\text{-N}(\text{H})-$ , and  $-\text{CH}_2\text{-N}(\text{R})-$  where R is selected from hydrogen and  $\text{C}_{1-4}$ -alkyl. Amino-LNA can be in both beta-D and alpha-L-configuration.

The term "oxy-LNA" comprises a locked nucleotide in which Y in the general formula above represents  $-\text{O}-$ . Oxy-LNA can be in both beta-D and alpha-L-configuration.

10 The term "ENA" comprises a locked nucleotide in which Y in the general formula above is  $-\text{CH}_2\text{-O-}$  (where the oxygen atom of  $-\text{CH}_2\text{-O-}$  is attached to the 2'-position relative to the base B).  $\text{R}^{\text{e}}$  is hydrogen or methyl.

In some exemplary embodiments LNA is selected from beta-D-oxy-LNA, alpha-L-oxy-LNA, beta-D-amino-LNA and beta-D-thio-LNA, in particular beta-D-oxy-LNA.

15 **Conjugates**

In the context the term "conjugate" is intended to indicate a heterogenous molecule formed by the covalent attachment ("conjugation") of the oligomer as described herein to one or more non-nucleotide, or non-polynucleotide moieties. Examples of non-nucleotide or non- polynucleotide moieties include macromolecular agents such as proteins, fatty acid chains, sugar residues, glycoproteins, polymers, or combinations thereof. Typically proteins may be antibodies for a target protein. Typical polymers may be polyethylene glycol.

Therefore, in various embodiments, the oligomer of the invention may comprise both a polynucleotide region which typically consists of a contiguous sequence of nucleotides, and

a further non-nucleotide region. When referring to the oligomer of the invention consisting of a contiguous nucleotide sequence, the compound may comprise non-nucleotide components, such as a conjugate component.

In various embodiments of the invention the oligomeric compound is linked to

5 ligands/conjugates, which may be used, e.g. to increase the cellular uptake of oligomeric compounds. WO2007/031091 provides suitable ligands and conjugates, which are hereby incorporated by reference.

The invention also provides for a conjugate comprising the compound according to the invention as herein described, and at least one non-nucleotide or non-polynucleotide moiety 10 covalently attached to said compound. Therefore, in various embodiments where the compound of the invention consists of a specified nucleic acid or nucleotide sequence, as herein disclosed, the compound may also comprise at least one non-nucleotide or non-polynucleotide moiety (e.g. not comprising one or more nucleotides or nucleotide analogues) covalently attached to said compound.

15 In some embodiments, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of carbohydrates, cell surface receptor ligands, drug substances, hormones, a protein, such as an enzyme, an antibody or an antibody fragment or a peptide; a lipophilic substances, polymers, proteins, peptides, toxins (e.g. bacterial toxins), vitamins, viral proteins (e.g. capsids) or combinations thereof moiety such as a lipid, a phospholipid, a 20 sterol; a polymer, such as polyethyleneglycol or polypropylene glycol; a receptor ligand; a small molecule; a reporter molecule; and a non-nucleosidic carbohydrate.

Conjugation (to a conjugate moiety) may enhance the activity, cellular distribution or cellular uptake of the oligomer of the invention. Such moieties include, but are not limited to, antibodies, polypeptides, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, 25 e.g. Hexyl-s-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipids, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-o-hexadecyl-rac-glycero-3-h-phosphonate, a polyamine or a polyethylene glycol chain, an adamantane acetic acid, a palmityl moiety, an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety.


30 The oligomers of the invention may also be conjugated to active drug substances, for example, aspirin, ibuprofen, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

In certain embodiments the conjugated moiety is a sterol, such as cholesterol.

In various embodiments, the conjugated moiety comprises or consists of a positively charged polymer, such as a positively charged peptides of, for example from 1 - 50, such as 35 2 – 20 such as 3 – 10 amino acid residues in length, and/or polyalkylene oxide such as

polyethylglycol(PEG) or polypropylene glycol – see WO 2008/034123, hereby incorporated by reference. Suitably the positively charged polymer, such as a polyalkylene oxide may be attached to the oligomer of the invention via a linker such as the releasable inker described in WO 2008/034123.

5 By way of example, the following GalNAc conjugate moieties may be used in the conjugates of the invention:



10 The invention further provides a conjugate comprising the oligomer according to the invention, which comprises at least one non-nucleotide or non-polynucleotide moiety (“conjugated moiety”) covalently attached to the oligomer of the invention. In some embodiments the conjugate of the invention is covalently attached to the oligomer via a biocleavable linker, which, for example may be a region of phosphodiester linked  
 15 nucleotides, such as 1 – 5 PO linked DNA nucleosides (WO2014/076195, hereby incorporated by reference ). Preferred conjugate groups include carbohydrate conjugates, such as GalNAc conjugates, such as trivalent GalNAc conjugates (e.g. see WO2014/118267, hereby incorporated by reference) or lipophilic conjugates, such as a sterol, e.g. cholesterol (WO2014/076195, hereby incorporated by reference)

20 **Activated oligomers**

The term “activated oligomer,” as used herein, refers to an oligomer of the invention that is covalently linked (i.e., functionalized) to at least one functional moiety that permits covalent linkage of the oligomer to one or more conjugated moieties, i.e., moieties that are not themselves nucleic acids or monomers, to form the conjugates herein described.

25 Typically, a functional moiety will comprise a chemical group that is capable of covalently

bonding to the oligomer via, e.g., a 3'-hydroxyl group or the exocyclic NH<sub>2</sub> group of the adenine base, a spacer that is preferably hydrophilic and a terminal group that is capable of binding to a conjugated moiety (e.g., an amino, sulfhydryl or hydroxyl group). In some embodiments, this terminal group is not protected, e.g., is an NH<sub>2</sub> group. In other

5 embodiments, the terminal group is protected, for example, by any suitable protecting group such as those described in "Protective Groups in Organic Synthesis" by Theodora W Greene and Peter G M Wuts, 3rd edition (John Wiley & Sons, 1999). Examples of suitable hydroxyl protecting groups include esters such as acetate ester, aralkyl groups such as benzyl, diphenylmethyl, or triphenylmethyl, and tetrahydropyran. Examples of suitable 10 amino protecting groups include benzyl, alpha-methylbenzyl, diphenylmethyl, triphenylmethyl, benzyloxycarbonyl, tert-butoxycarbonyl, and acyl groups such as trichloroacetyl or trifluoroacetyl. In some embodiments, the functional moiety is self-cleaving. In other embodiments, the functional moiety is biodegradable. See e.g., U.S. Patent No. 7,087,229, which is incorporated by reference herein in its entirety.

15 In some embodiments, oligomers of the invention are functionalized at the 5' end in order to allow covalent attachment of the conjugated moiety to the 5' end of the oligomer. In other embodiments, oligomers of the invention can be functionalized at the 3' end. In still other embodiments, oligomers of the invention can be functionalized along the backbone or on the heterocyclic base moiety. In yet other embodiments, oligomers of the invention can 20 be functionalized at more than one position independently selected from the 5' end, the 3' end, the backbone and the base.

In some embodiments, activated oligomers of the invention are synthesized by incorporating during the synthesis one or more monomers that is covalently attached to a functional moiety. In other embodiments, activated oligomers of the invention are 25 synthesized with monomers that have not been functionalized, and the oligomer is functionalized upon completion of synthesis. In some embodiments, the oligomers are functionalized with a hindered ester containing an aminoalkyl linker, wherein the alkyl portion has the formula (CH<sub>2</sub>)<sub>w</sub>, wherein w is an integer ranging from 1 to 10, preferably about 6, wherein the alkyl portion of the alkylamino group can be straight chain or branched chain, 30 and wherein the functional group is attached to the oligomer via an ester group (-O-C(O)- (CH<sub>2</sub>)<sub>2</sub>NH).

In other embodiments, the oligomers are functionalized with a hindered ester containing a (CH<sub>2</sub>)<sub>2</sub>-sulfhydryl (SH) linker, wherein w is an integer ranging from 1 to 10, preferably about 6, wherein the alkyl portion of the alkylamino group can be straight chain or

branched chain, and wherein the functional group attached to the oligomer via an ester group (-O-C(O)-(CH<sub>2</sub>)<sub>2</sub>SH)

In some embodiments, sulphydryl-activated oligonucleotides are conjugated with polymer moieties such as polyethylene glycol or peptides (via formation of a disulfide bond).

5        Activated oligomers containing hindered esters as described above can be synthesized by any method known in the art, and in particular by methods disclosed in PCT Publication No. WO 2008/034122 and the examples therein, which is incorporated herein by reference in its entirety.

10      In still other embodiments, the oligomers of the invention are functionalized by introducing sulphydryl, amino or hydroxyl groups into the oligomer by means of a functionalizing reagent substantially as described in U.S. Patent Nos. 4,962,029 and 4,914,210, i.e., a substantially linear reagent having a phosphoramidite at one end linked through a hydrophilic spacer chain to the opposing end which comprises a protected or unprotected sulphydryl, amino or hydroxyl group. Such reagents primarily react with hydroxyl 15 groups of the oligomer. In some embodiments, such activated oligomers have a functionalizing reagent coupled to a 5'-hydroxyl group of the oligomer. In other embodiments, the activated oligomers have a functionalizing reagent coupled to a 3'-hydroxyl group. In still other embodiments, the activated oligomers of the invention have a functionalizing reagent coupled to a hydroxyl group on the backbone of the oligomer. In yet 20 further embodiments, the oligomer of the invention is functionalized with more than one of the functionalizing reagents as described in U.S. Patent Nos. 4,962,029 and 4,914,210, incorporated herein by reference in their entirety. Methods of synthesizing such functionalizing reagents and incorporating them into monomers or oligomers are disclosed in U.S. Patent Nos. 4,962,029 and 4,914,210.

25      In some embodiments, the 5'-terminus of a solid-phase bound oligomer is functionalized with a dienyl phosphoramidite derivative, followed by conjugation of the deprotected oligomer with, e.g., an amino acid or peptide via a Diels-Alder cycloaddition reaction.

30      In various embodiments, the incorporation of monomers containing 2'-sugar modifications, such as a 2'-carbamate substituted sugar or a 2'-(O-pentyl-N-phthalimido)-deoxyribose sugar into the oligomer facilitates covalent attachment of conjugated moieties to the sugars of the oligomer. In other embodiments, an oligomer with an amino-containing linker at the 2'-position of one or more monomers is prepared using a reagent such as, for example, 5'-dimethoxytrityl-2'-O-(e-phthalimidylaminopentyl)-2'-deoxyadenosine-3'-- N,N-

diisopropyl-cyanoethoxy phosphoramidite. See, e.g., Manoharan, et al., *Tetrahedron Letters*, 1991, 34, 7171.

In still further embodiments, the oligomers of the invention may have amine-containing functional moieties on the nucleobase, including on the N6 purine amino groups, 5 on the exocyclic N2 of guanine, or on the N4 or 5 positions of cytosine. In various embodiments, such functionalization may be achieved by using a commercial reagent that is already functionalized in the oligomer synthesis.

Some functional moieties are commercially available, for example, heterobifunctional and homobifunctional linking moieties are available from the Pierce Co. 10 (Rockford, Ill.). Other commercially available linking groups are 5'-Amino-Modifier C6 and 3'-Amino-Modifier reagents, both available from Glen Research Corporation (Sterling, Va.). 5'-Amino-Modifier C6 is also available from ABI (Applied Biosystems Inc., Foster City, Calif.) as Aminolink-2, and 3'-Amino-Modifier is also available from Clontech Laboratories Inc. (Palo Alto, Calif.). In some embodiments in some embodiments

### 15 **Compositions**

The oligomer of the invention may be used in pharmaceutical formulations and compositions. Suitably, such compositions comprise a pharmaceutically acceptable diluent, carrier, salt or adjuvant. PCT/DK2006/000512 provides suitable and preferred pharmaceutically acceptable diluent, carrier and adjuvants - which are hereby incorporated 20 by reference. Suitable dosages, formulations, administration routes, compositions, dosage forms, combinations with other therapeutic agents, pro-drug formulations are also provided in PCT/DK2006/000512 - which are also hereby incorporated by reference.

### **Applications**

The oligomers of the invention may be utilized as research reagents for, for example, 25 diagnostics, therapeutics and prophylaxis.

In research, such oligomers may be used to specifically inhibit the synthesis of a target protein (typically by degrading or inhibiting the mRNA and thereby prevent protein formation) in cells and experimental animals thereby facilitating functional analysis of the target or an appraisal of its usefulness as a target for therapeutic intervention.

30 In diagnostics the oligomers may be used to detect and quantitate a target expression in cell and tissues by northern blotting, *in-situ* hybridisation or similar techniques.

For therapeutics, an animal or a human, suspected of having a disease or disorder, which can be treated by modulating the expression of a target is treated by administering oligomeric compounds in accordance with this invention. Further provided are methods of

treating a mammal, such as treating a human, suspected of having or being prone to a disease or condition, associated with expression of a target by administering a therapeutically or prophylactically effective amount of one or more of the oligomers or compositions of the invention. The oligomer, a conjugate or a pharmaceutical composition

5 according to the invention is typically administered in an effective amount.

The invention also provides for the use of the compound or conjugate of the invention as described for the manufacture of a medicament for the treatment of a disorder as referred to herein, or for a method of the treatment of a disorder as referred to herein.

The invention also provides for a method for treating a disorder as referred to herein

10 said method comprising administering a compound according to the invention as herein described, and/or a conjugate according to the invention, and/or a pharmaceutical composition according to the invention to a patient in need thereof.

### ***Medical Indications***

The oligomers and other compositions according to the invention can be used for the

15 treatment of conditions associated with over expression or expression of mutated version of the target.

The invention further provides use of a compound of the invention in the manufacture of a medicament for the treatment of a disease, disorder or condition as referred to herein.

Generally stated, one aspect of the invention is directed to a method of treating a

20 mammal suffering from or susceptible to conditions associated with abnormal levels of the target, comprising administering to the mammal and therapeutically effective amount of an oligomer targeted to the target that comprises one or more LNA units. The oligomer, a conjugate or a pharmaceutical composition according to the invention is typically administered in an effective amount.

### **25 Embodiments**

1. An LNA oligonucleotide comprising a central region (Y') of at least 5 or more contiguous nucleosides, and a 5' wing region (X') comprising of 1 – 6 LNA nucleosides and a 3' wing region (Z') comprising of LNA 1 – 6 nucleosides, wherein at least one of the internucleoside linkages of central region is stereospecified, and wherein the central
- 30 region comprises both Rp and Sp internucleoside linkages.
2. The LNA oligonucleotide of embodiment 1, wherein only 1, 2, 3, 4 or 5 of the internucleoside linkages of the central region (Y') are stereoselective phosphorothioate linkages, and the remaining internucleoside linkages are randomly Rp or Sp.
3. The LNA oligonucleotide of embodiment 1, wherein all of the internucleoside linkages of
- 35 the central region (Y') are stereoselective phosphorothioate linkages.

4. The LNA oligonucleotide of any one of embodiments 1 – 4, wherein the central region (Y') comprises at least 5 contiguous phosphorothioate linked DNA nucleoside.
5. The LNA oligonucleotide of any one of embodiments 1 – 5, wherein the central region is at least 8 or 9 DNA nucleosides in length.
- 5 6. The LNA oligonucleotide of any one of embodiments 1 – 5, wherein the central region is at least 10 or 11 DNA nucleosides in length.
7. The LNA oligonucleotide of any one of embodiments 1 – 5, wherein the central region is at least 12 or 13 DNA nucleosides in length.
8. The LNA oligonucleotide of any one of embodiments 1 – 5, wherein the central region is 10 at least 14 or 15 DNA nucleosides in length.
9. The LNA oligonucleotide according to any one of embodiments 1 – 8, wherein the internucleoside linkages of the central region (Y') are either Rp or Sp phosphorothioate linkages, and wherein at least one of the wing regions (X' or Z') comprises at least one stereoselective phosphorothioate linkage between an LNA nucleoside and a subsequent 15 (3') nucleoside.
10. The LNA oligonucleotide according to any one of embodiments 1 - 9, which comprises at least one stereospecific phosphorothioate nucleotide pair wherein the internucleoside linkage between the nucleotides pair is either in the Rp configuration or in the Rs configuration, and wherein at least one of the nucleosides of the nucleotide pair is a LNA 20 nucleotide.
11. The LNA oligonucleotide of embodiment 10, wherein the other nucleotide of the nucleotide pair is other than DNA, such as nucleoside analogue, such as a further LNA nucleoside or a 2' substituted nucleoside.
12. The LNA oligonucleotide of any one of embodiments 1 - 11, wherein at least one of the 25 internucleoside linkages linking the nucleosides of the central region (Y'), or linking the 3' nucleoside of region Y' with the first nucleoside of the 3' wing (X'), is a stersoselective phosphorothioate linkage.
13. The LNA oligonucleotide according to any one of embodiments 1 – 12, wherein each wing region comprises 1, 2 or 3 LNA nucleosides.
- 30 14. The LNA oligonucleotide according to any one of embodiments 1 – 13, wherein at least one wing region comprises a 2' substituted nucleoside.
15. The LNA oligonucleotide according to embodiment 14, wherein the 2' substituted nucleoside is selected from the group consisting of 2'-O-MOE and 2'fluoro.

16. The LNA oligonucleotide according to any one of embodiments 1 – 13, wherein the nucleosides of the 5' (X') and 3' (Z') wing regions comprise or consist of LNA nucleosides/nucleotides, such as beta-D-oxy LNA nucleosides/nucleotides.
17. The LNA oligonucleotide according to any one of embodiments 1 – 16, wherein the 5 length of oligomer or the length of the contiguous sequence of nucleosides in regions X'-Y'-Z' is 10 – 20, such as 10 – 16 in length.
18. The LNA oligonucleotide according to any one of embodiments 1 – 17, wherein the 10 number of nucleosides in each region (X'-Y'-Z') is selected from the group consisting of 1-8-1, 1-8-2, 2-8-1, 2-8-2, 3-8-3, 2-8-3, 3-8-2, 4-8-1, 4-8-2, 1-8-4, 2-8-4, or; 1-9-1, 1-9-2, 2-9-1, 2-9-2, 2-9-3, 3-9-2, 1-9-3, 3-9-1, 4-9-1, 1-9-4, or; 1-10-1, 1-10-2, 2-10-1, 2-10-2, 1-10-3, and 3-10-1.
19. The LNA oligonucleotide according to any one of embodiments 1 – 17, wherein the 15 number of nucleosides in each region (X'-Y'-Z') is selected from the group consisting of 3-10-3, 3-10-4, 4-10-3, 3-9-3, 3-9-4, 4-9-3, 3-8-3, 3-8-4, 4-8-3, 3-7-3, 3-7-4, 4-7-3.
20. The LNA oligonucleotide according to any one of embodiments 1 – 17, wherein the 20 number of nucleosides in each region (X'-Y'-Z') is selected from the group consisting of 3-10-3, 3-11-3, 3-12-3, 3-13-3, 3-14-3, 2-10-2, 2-11-2, 2-11-2, 2-12-2, 2-13-2, 2-14-2, 2-10-3, 3-10-2, 2-11-3, 3-11-2, 3-12-2, 2-12-3, 3-12-2, 2-12-3, 3-13-2, 2-12-3, 3-13-2, 2-13-3, 3-14-2 and 2-14-3.
21. The LNA oligonucleotide according to any one of embodiments 1 – 20, wherein the 25 5' wing region comprises at least one stereospecific phosphorothioate linkage, Rp or Sp.
22. The LNA oligonucleotide according to embodiment 21 wherein the remaining internucleoside linkages are not stereospecified.
23. The LNA oligonucleotide according to any one of embodiments 1 – 20, wherein the 3' 30 wing region comprises at least one stereospecific phosphorothioate linkage, Rp or Sp.
24. The LNA oligonucleotide according to embodiment 23 wherein the remaining internucleoside linkages are not stereospecified.
25. The LNA oligonucleotide according to any one of embodiments 1 – 20, wherein both the 5' and the 3' wing region each comprises at least one stereospecific phosphorothioate 35 linkage, independently or dependently selected from Rp or Sp.
26. The LNA oligonucleotide according to embodiment 25 wherein the remaining internucleoside linkages are not stereospecified phosphorothioate linkages.
27. The LNA oligonucleotide according to any one of embodiments 1 – 26 wherein all the internucleoside linkages in the gapmer (X'-Y'-Z') are phosphorothioate linkages.

28. The LNA oligonucleotide according to any one of embodiments 1 – 27, wherein the sequence X'-Y'-Z' is complementary to a target sequence present in a target nucleic acid present in Table 1.
29. The LNA oligonucleotide according to any one of embodiments 1 – 28, wherein the gap 5 region Y' comprises a DNA dinucleotide motif selected from the group consisting of cc, tg, tc, ac, tt, gt, ca and gc, wherein the internucleoside linkage between the DNA nucleosides of the dinucleotide is a stereospecific phosphorothioate linkage such as either a Sp or a Rp phosphorothioate internucleoside linkage.
30. The LNA oligonucleotide according to any one of embodiments 1 – 29, wherein the LNA 10 oligonucleotide has an enhanced human RNaseH recruitment activity as compared to an equivalent non stereoselective LNA oligonucleotide, for example using the RNaseH recruitment assays provided in example 7.
31. The LNA oligonucleotide according to any one of embodiments 1 – 30, wherein the LNA oligonucleotide has reduced toxicity as compared to an equivalent non stereoselective 15 LNA oligonucleotide, e.g. reduced *in vivo* hepatotoxicity, for example as measured using the assay provided in example 6 or 8, or reduced nephrotoxicity, e.g. as measured using the assay provided in example 9.
32. The LNA oligonucleotide according to any one of embodiments 1 – 30, wherein the LNA oligonucleotide has an altered biodistribution *in vivo* or *in vitro*.
33. A conjugate comprising the stereoselective phosphorothioate LNA oligonucleotide of any one of embodiments 1 – 32 covalently attached to a non-nucleoside moiety. 20
34. The conjugate according to embodiment 33, wherein the conjugate moiety is a GalNAc, such as a GalNAc2.
35. The conjugate according to embodiment 33 or 34, wherein the conjugate moiety is 25 covalently attached to the 5' or 3' of the LNA oligonucleotide via a region of 1, 2 or 3 phosphodiester linked DNA nucleosides.
36. A pharmaceutical composition comprising the stereoselective phosphorothioate LNA oligonucleotide of any one of embodiments 1 – 32 or the conjugate of any one of embodiments 33 - 35 and an a pharmaceutically acceptable solvent,(such as water or 30 saline water), diluent, carrier, salt or adjuvant.
37. The stereoselective phosphorothioate LNA oligonucleotide of any one of embodiments 1 – 32 or the conjugate of any one of embodiments 33-35, for use in medicine.
38. A method of reducing the toxicity of a stereo unspecified phosphorothioate oligonucleotide sequence, comprising the steps of:

- a. Providing a stereo unspecified phosphorothioate oligonucleotide which has a toxicity phenotype *in vivo* or *in vitro*
- b. Creating a library of stereo specified phosphorothioate oligonucleotides, retaining the core nucleobase sequence of the parent gapmer oligonucleotide
- 5 c. Screening the library created in step b. in an *in vivo* or *in vitro* toxicity assay to
- d. Identify one or more stereo specified phosphorothioate oligonucleotides which have a reduced toxicity as compared to the stereo unspecified phosphorothioate oligonucleotide.

39. The use of a stereospecified phosphorothioate internucleoside linkage in an oligonucleotide, wherein the oligonucleotide has a reduced toxicity as compared to an identical oligonucleotide which does not comprise the sterospecified phosphorothioate internucleotide linkage.

10 40. The use of a stereospecific phosphorothioate monomer (e.g. phosphoramidite) for the synthesis for a reduced toxicity oligonucleotide.

15

## EXAMPLES


### Sequences

The compounds used herein have the following nucleobase sequences:


actgcttccactctg	SEQ ID NO 1
tcatggctgcagct	SEQ ID NO 2
gcattggattca	SEQ ID NO 3
cacattccttgctctg	SEQ ID NO 4

20 **Example 1**

Synthesis of DNA 3'-O-oxazaphospholidine monomers was performed as previously described (Oka et al., J. Am. Chem. Soc. 2008 130: 16031 – 16037, and Wan et al., NAR 2014, November, online publication).

*Synthesis of LNA 3'-O-oxazaphospholidine monomers**Synthesis scheme*

**$\alpha$ -Phenyl-2-pyrrolidinemethanol (P5-L and P5-D)** was synthesized as described in the literature (Oka *et al.*, *JACS*, **2008**, 16031-16037.)

3-OAP-LNA T**Synthesis of L-3-OAP-LNA T:**

PCl<sub>3</sub> (735 $\mu$ L, 6.30mmol) was dissolved in toluene (7mL), cooled to 0 °C (ice bath) and a solution of **P5-L** (1.12g, 6.30mmol) and NMM (1.38mL, 12.6mmol) in toluene (7mL) was added dropwise. The reaction mixture was stirred at room temperature for 1h, and then cooled to -72 °C. Precipitates were filtered under argon, washed with toluene (4mL) and filtrate was concentrated at 40 °C and reduced pressure (*Schlenk technique*). The residue was dissolved in THF (8mL) and used in the next step.

To a solution of 5'-ODMT-LNA-T (2.40g, 4.20mmol) in THF (16mL), NEt<sub>3</sub> (4.10mL, 29.4mmol) was added. The reaction mixture was cooled to -74 °C and the solution of 2-chloro-1,3,2-oxazaphospholidine in THF was added dropwise. The reaction mixture was stirred for 4h at room temperature. EtOAc was added and the reaction mixture was extracted with sat. NaHCO<sub>3</sub> (2 times), brine, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by column chromatography (eluent hexanes/EtOAc 30/70 + NEt<sub>3</sub> 6 %). Product was isolated as white foam 1.00g (yield 30%). <sup>1</sup>H-NMR spectrum (400 MHz): (DMSO-d<sub>6</sub>)  $\delta$ : 11.53 (1H, s), 7.64 (1H, m), 7.46-7.41 (2H, m), 7.40 -7.19 (12H, m), 6.92-6.83 (4H, m), 5.51 (1H, d,  $J$  = 6.3 Hz), 5.49 (1H, s), 4.78 (1H, d,  $J$  = 7.4 Hz), 4.37 (1H, s), 3.91 (1H, m), 3.76 -3.67 (2H, m), 3.72 (3H, s), 3.71 (3H, s), 3.50 (1H, m), 3.41 (2H, s), 2.90 (1H, m), 1.60-1.46 (2H,

m), 1.51 (3H, s), 1.15 (1H, m), 0.82 (1H, m).  $^{31}\text{P}$ -NMR spectrum (160 MHz): (DMSO-d<sub>6</sub>)  $\delta$ : 151.3. LCMS ESI (m/z): 776.2 [M-H]<sup>-</sup>.


### Synthesis of D-3-OAP-LNA T

5  $\text{PCl}_3$  (1.05mL, 9.0mmol) was dissolved in toluene (12mL), cooled to 0 °C (ice bath) and a solution of **P5-D** (1.13g, 12mmol) and NMM (2.06mL, 24mmol) in toluene (12mL) was added dropwise. The reaction mixture was stirred at room temperature for 1h, and then cooled to -72 °C. Precipitates were filtered under argon, washed with toluene and filtrate was concentrated at 40 °C and reduced pressure (*Schlenk technique*). The residue was dissolved in THF (18mL) and used in the next step.

10 To a solution of 5'-ODMT-LNA-T (3.44g, 6.0mmol) in THF (30mL),  $\text{NEt}_3$  (5.82mL, 42mmol) was added. The reaction mixture was cooled to -74 °C and the solution of 2-chloro-1,3,2-oxazaphospholidine in THF was added dropwise. The reaction mixture was stirred for 4h at room temperature. EtOAc was added and the reaction mixture was extracted with sat.  $\text{NaHCO}_3$  (2 times), brine, dried over  $\text{Na}_2\text{SO}_4$  and evaporated. The residue was purified by 15 column chromatography (eluent hexanes/EtOAc 30/70 +  $\text{NEt}_3$  6 %). Product was isolated as a white foam 1.86 g (yield 36%),  $^1\text{H}$ -NMR spectrum (400 MHz): (DMSO-d<sub>6</sub>)  $\delta$ : 11.55 (1H, s), 7.60 (1H, m), 7.46-7.41 (2H, m), 7.39-7.22 (12H, m), 6.91-6.84 (4H, m), 5.66 (1H, d,  $J$  = 6.3 Hz), 5.51 (1H, s), 4.60 (1H, d,  $J$  = 7.4 Hz), 4.41 (1H, s), 3.80-3.70 (3H, m), 3.72 (3H, s), 3.71 (3H, s), 3.48-3.37 (3H, m), 2.96 (1H, m), 1.61-1.43 (2H m), 1.51 (3H, s) 1.10 (1H, m), 0.80 (1H, m).  $^{31}\text{P}$ -NMR spectrum (160 MHz): (DMSO-d<sub>6</sub>)  $\delta$ : 152.5. LCMS ESI (m/z): 776.2 [M-H]<sup>-</sup>.

20

### 3-OAP-LNA MeC



### Synthesis of L-3-OAP-LNA MeC

25  $\text{PCl}_3$  (110 $\mu\text{L}$ , 1.25mmol) was dissolved in toluene (3mL), cooled to 0 °C (ice bath) and a solution of **P5-L** (222mg, 1.25mmol) and NMM (275 $\mu\text{L}$ , 2.5mmol) in toluene (3mL) was added dropwise. The reaction mixture was stirred at room temperature 45 min, and then cooled to -72 °C. Precipitates were filtered under argon, washed with toluene and filtrate was concentrated at 40 °C at reduced pressure (*Schlenk technique*). The residue was dissolved in THF (5mL) and used in the next step.


To solution of 5'-ODMT-LNA-C (338mg, 0.50mmol) in THF (2.5mL)  $\text{NEt}_3$  (485 $\mu\text{L}$ , 3.6mmol) was added. The reaction mixture cooled to  $-70$  °C and the solution of phosphor 2-chloro-1,3,2-oxazaphospholidine was added dropwise. The reaction mixture was stirred for 1.45 h at room temperature.  $\text{EtOAc}$  (30 mL) was added and the reaction mixture was extracted with 5 sat.  $\text{NaHCO}_3$  (2 $\times$ 20 mL), brine (20 mL), dried over  $\text{Na}_2\text{SO}_4$  and evaporated. The residue was purified by column chromatography (eluent  $\text{EtOAc}$  in hexanes from 20% to 30% + toluene 10 %+  $\text{NEt}_3$  7 %). Product isolated as white foam 228mg (yield 47%).  $^1\text{H-NMR}$  spectrum (400 MHz): ( $\text{CD}_3\text{CN}$ )  $\delta$ : 13.3 (1H, br s), 8.41-8.25 (2H, m), 7.88 (1H, m), 7.59 (1H, m), 7.54-7.47 (4H, m), 7.41-7.19 (12H, m), 6.90-6.79 (4H, m), 5.62 (1H, m), 5.58 (1H, s), 4.79 (1H, d,  $J$  = 7.5 Hz), 4.47 (1H, s), 3.93 (1H, m), 3.86 (1H, m), 3.75 (1H, m), 3.76 (3H, s), 3.75 (3H, s), 3.60-3.47 (3H, m), 2.99 (1H, m), 1.83 (3H, d,  $J$  = 1.2 Hz), 1.65-1.51 (2H, m), 1.17 (1H, m), 10 0.89 (1H, m).  $^{31}\text{P-NMR}$  spectrum (160 MHz): ( $\text{CD}_3\text{CN}$ )  $\delta$ : 153.4. LCMS ESI (m/z): 881.2 [M+H]<sup>+</sup>.

### Synthesis of D-3-OAP-LNA MeC

15  $\text{PCl}_3$  (1.10mL, 12.3mmol) was dissolved in toluene (10mL), cooled to 0 °C (ice bath) and solution of **P5-D** (2.17g, 12.3mmol) and NMM (2.70mL, 2.5mmol) in toluene (10mL) was added dropwise. The reaction mixture was stirred at room temperature 45min, and then cooled to  $-72$  °C. Precipitates were filtered under argon, washed with toluene and filtrate was concentrated at 40 °C at reduced pressure (*Schlenk technique*). The residue was dissolved 20 in THF (10mL) and used in the next step.

To solution of 5'-ODMT-LNA-C (3.38g, 5mmol) in THF (20mL)  $\text{NEt}_3$  (4.85mL, 35mmol) was added. The reaction mixture cooled to  $-70$  °C and the solution of phosphor 2-chloro-1,3,2-oxazaphospholidine was added dropwise. The reaction mixture was stirred for 1.45 h at room temperature.  $\text{EtOAc}$  was added and the reaction mixture was extracted with sat. 25  $\text{NaHCO}_3$  (2 $\times$ times), brine, dried over  $\text{Na}_2\text{SO}_4$ , and evaporated. The residue was purified by column chromatography (eluent  $\text{EtOAc}$  in hexanes from 20% to 30% + toluene 10 %+  $\text{NEt}_3$  7 %). Product was isolated as white foam 1.09g (yield 23%).  $^1\text{H-NMR}$  spectrum (400 MHz): ( $\text{CD}_3\text{CN}$ )  $\delta$ : 12.8 (1H, br s), 8.34-8.24 (2H, m), 7.85 (1H, d,  $J$  = 1.2 Hz), 7.57 (1H, m), 7.53-7.45 (4H, m), 7.41-7.22 (12H, m), 6.89-6.84 (4H, m), 5.72 (1H, d,  $J$  = 6.5 Hz), 5.59 (1H, s), 30 4.62 (1H, d,  $J$  = 8.0 Hz), 4.52 (1H, s), 3.82 (2H, dd,  $J$  = 24.4 8.2 Hz), 3.77 (1H, m), 3.76 (3H, s), 3.75 (3H, s), 3.51 (2H, s), 3.46 (1H, m), 3.05 (1H, m), 1.81 (3H, s), 1.65-1.47 (2H, m), 1.12 (1H, m), 0.85 (1H, m).  $^{31}\text{P-NMR}$  spectrum (160 MHz): ( $\text{CD}_3\text{CN}$ )  $\delta$ : 153.5. LCMS ESI (m/z): 881.2 [M+H]<sup>+</sup>.

### 3-OAP-LNA A



## Synthesis of L-3-OAP-LNA A

5  $\text{PCl}_3$  (184 $\mu\text{L}$ , 2.1mmol) was dissolved in toluene (5 mL), cooled to 0 °C (ice bath) and a solution of **P5-L** (373mg, 2.10mmol) and NMM (463 $\mu\text{L}$ , 4.20mmol) in toluene (5 mL) was added dropwise. The reaction mixture was stirred at room temperature for 45 min, and then cooled to -72 °C. Precipitates was filtered under argon, washed with toluene (4 mL) and filtrate was concentrated at 40 °C at reduce pressure (*Schlenk technique*). The residue was dissolved in THF (5 mL) and used in the next step.

10 To a solution of 5'-ODMT-LNA-A (960mg, 1.40mmol) in THF (7mL)  $\text{NEt}_3$  (1.36mL, 9.80mmol) was added. The reaction mixture cooled to -70 °C and the solution of phosphor 2-chloro-1,3,2-oxazaphospholidine was added dropwise. The reaction mixture was stirred for 4 h at room temperature.  $\text{EtOAc}$  (50 mL) was added and the reaction mixture was extracted with sat.  $\text{NaHCO}_3$  (2 $\times$ 30 mL), brine (30 mL), dried over  $\text{Na}_2\text{SO}_4$  and evaporated. The residue was purified by column chromatography (eluent hexanes/ $\text{EtOAc}$  30/70 +  $\text{NEt}_3$  6-7 %).

15 Product isolated as white foam 455mg (yield 35%).  $^1\text{H-NMR}$  spectrum (400 MHz): (DMSO- $d_6$ )  $\delta$ : 11.33 (1H, s), 8.76 (1H, s), 8.53 (1H, s), 8.11-8.02 (2H, m), 7.66 (1H, m), 7.60-7.53 (2H, m), 7.44-7.38 (2H, m), 7.35-7.18 (10H, m), 7.05-6.99 (2H, m), 6.89-6.82 (4H, m), 6.21 (1H, s), 5.27 (1H, d,  $J$  = 6.6 Hz), 5.19 (1H, d,  $J$  = 7.9 Hz), 4.81 (1H, s), 3.93 (2H, dd,  $J$  = 29.0 Hz), 3.77 (1H, m), 3.71 (6H, s), 3.51-3.35 (3H, m), 2.70 (1H, m), 1.56-1.34 (2H, m), 1.10 (1H, m), 0.73 (1H, m).  $^{31}\text{P-NMR}$  spectrum (160 MHz): (DMSO- $d_6$ )  $\delta$ : 149.9. LCMS ESI (m/z): 891.1 [M+H] $^+$ .

## Synthesis of D-3-OAP-LNA A

25  $\text{PCl}_3$  0.84mL, 9.63mmol) was dissolved in toluene (12 mL), cooled to 0 °C (ice bath) and a solution of **P5-D** (1.70g, 9.63mmol) and NMM (2.12mL, 19.3mmol) in toluene (12 mL) was added dropwise. The reaction mixture was stirred at room temperature for 45 min, and then cooled to -72 °C. Precipitates was filtered under argon, washed with toluene and filtrate was

concentrated at 40 °C at reduce pressure (*Schlenk technique*). The residue was dissolved in THF (12mL) and used in the next step.


To a solution of 5'-ODMT-LNA-A (3.77, 5.50mmol) in THF (20mL)  $\text{NEt}_3$  (5.30mL, 38.5mmol) was added. The reaction mixture cooled to  $-70^\circ\text{C}$  and the solution of phosphor 2-chloro-

5 1,3,2-oxazaphospholidine was added dropwise. The reaction mixture was stirred for 4 h at room temperature. EtOAc was added and the reaction mixture was extracted with sat.

$\text{NaHCO}_3$ , brine, dried over  $\text{Na}_2\text{SO}_4$  and evaporated. The residue was purified by column chromatography (eluent hexanes/EtOAc 30/70 +  $\text{NEt}_3$  6-7 %). Product was isolated as a white foam 1.86g (yield 36%).  $^1\text{H-NMR}$  spectrum (400 MHz): (DMSO- $\text{d}_6$ )  $\delta$ : 11.28 (1H, s).

10 8.78 (1H, s), 8.54 (1H, s), 8.09 -8.04 (2H, m), 7.67 (1H, m), 7.60-7.54 (2H, m), 7.42-7.15 (14H, m), 6.89-6.82 (4H, m), 6.21 (1H, s), 5.58 (1H, d,  $J$  = 6.7 Hz), 5.02 (1H, d,  $J$  = 8.1 Hz), 4.89 (1H, s), 3.96 (2H, dd,  $J$  = 35.4 8.2 Hz), 3.71 (3H, s), 3.70 (3H, s), 3.53-3.33 (4H, m), 2.90 (1H, m), 1.54-1.37 (2H, m), 0.98 (1H, m), 0.71 (1H, m).  $^{31}\text{P}$ -NMR spectrum (160 MHz): (DMSO- $d_6$ )  $\delta$ : 150.6, 150.5 (2%), 150.4. LCMS ESI (m/z): 891.1 [M+H] $^+$ .

## 15 3-OAP-LNA G



## Synthesis of D-3-OAP-LNA G

20  $\text{PCl}_3$  (1.09mL, 12.4mmol) was dissolved in toluene (12.5 mL), cooled to 0 °C (ice bath) and a solution of **P5-D** (2.20g, 12.4mmol) and NMM (2.73mL, 27.8mmol) in toluene (12.5 mL) was added dropwise. The reaction mixture was stirred at room temperature for 45 min, and then cooled to -72 °C. Precipitates was filtered under argon, washed with toluene and filtrate was concentrated at 40 °C at reduce pressure (*Schlenk technique*). The residue was dissolved in THF (19mL) and used in the next step.

Before synthesis 5'-ODMT-LNA-G was co evaporated with toluene and then with pyridine (order is essential). To solution of 5'-ODMT-LNA-G (3.26g, 5.0mmol) in THF (15mL) and Pyridine (8mL),  $\text{NEt}_3$  (4.85mL, 35.0mmol) was added. The reaction mixture cooled to  $-70\text{ }^\circ\text{C}$  and the solution of phosphor 2-chloro-1,3,2-oxazaphospholidine was added dropwise. The reaction mixture was stirred for 2.5 h at room temperature.  $\text{EtOAc}$  was added and the

reaction mixture was extracted with sat.  $\text{NaHCO}_3$ , brine, dried over  $\text{Na}_2\text{SO}_4$  and evaporated. The residue was purified by column chromatography (eluent THF in EtOAc from 10% to 20 % +  $\text{NEt}_3$  6%). Product isolated as white foam 1.49g (yield 33%).  $^1\text{H-NMR}$  spectrum (400 MHz): (DMSO- $d_6$ )  $\delta$ : 11.42 (1H, s), 8.56 (1H, s), 7.95 (1H, s), 7.49-7.38 (2H, m), 7.36-7.16 (12H, m), 6.90-6.83 (4H, m), 5.96 (1H, s), 5.58 (1H, d,  $J$  = 6.7 Hz), 4.99 (1H, d,  $J$  = 8.2 Hz), 4.76 (1H, s), 3.96-3.85 (2H, m), 3.72 (6H, s), 3.62 -3.54 (1H, m), 3.45 (2H, s), 3.40-3.33 (1H, m), 3.08 (3H, s), 2.99 (3H, s), 2.93 -2.84 (1H, m), 1.53-1.39 (2H, m), 1.06-0.97 (1H, m), 0.79-0.63 (1H, m).  $^{31}\text{P-NMR}$  spectrum (160 MHz): (DMSO- $d_6$ )  $\delta$ : 151.6. LCMS ESI (m/z): 858.2  $[\text{M}+\text{H}]^+$ .

10 **Synthesis of L-3-OAP-LNA G**

15  $\text{PCl}_3$  (1.00mL, 11.4mmol) was dissolved in toluene (10 mL), cooled to 0 °C (ice bath) and a solution of **P5-L** (2.02g, 11.4mmol) and NMM (2.50mL, 22.7mmol) in toluene (10 mL) was added dropwise. The reaction mixture was stirred at room temperature for 45 min, and then cooled to -72 °C. Precipitates was filtered under argon, washed with toluene and filtrate was concentrated at 40 °C at reduce pressure (*Schlenk technique*). The residue was dissolved in THF (7mL) and used in the next step.

20 Before synthesis 5'-ODMT-LNA-G was co evaporated with toluene and then with pyridine (order is essential). To a solution of 5'-ODMT-LNA-G (2.86g, 4.54mmol) in THF (20mL) and Pyridine (12mL),  $\text{NEt}_3$  (4.40mL, 31.8mmol) was added. The reaction mixture cooled to -70 °C and the solution of phosphor 2-chloro-1,3,2-oxazaphospholidine was added dropwise. The reaction mixture was stirred for 2.5 h at room temperature. EtOAc was added and the reaction mixture was extracted with sat.  $\text{NaHCO}_3$ , brine, dried over  $\text{Na}_2\text{SO}_4$  and evaporated. The residue was purified by column chromatography (eluent THF in EtOAc from 10% to 20 % +  $\text{NEt}_3$  6%). Product isolated as white foam 1.44g (yield 34%).  $^1\text{H-NMR}$  (400MHz, DMSO- $d_6$ ):  $\delta$ : 11.44 (1H, s), 8.42 (1H, s), 7.94 (1H, s), 7.44-7.38 (2H, m), 7.34-7.23 (10H, m), 7.03-6.98 (2H, m), 5.94 (1H, s), 5.17 (1H, d,  $J$ =6.5Hz), 5.07 (1H, d,  $J$ =7.8Hz), 4.68 (1H, s), 3.88 (1H, d,  $J$ =8.2Hz), 3.84 (1H, d,  $J$ =8.2Hz), 3.73 (3H, s), 3.72 (3H, s), 3.68 (1H, m), 3.46-3.36 (3H, m), 3.05 (3H, s), 2.95 (3H, s), 2.77 (1H, m), 1.55-1.38 (2H, m), 1.07 (1H, m), 0.75 (1H, m).  $^{31}\text{P-NMR}$  (160MHz, DMSO- $d_6$ ):  $\delta$ : 148.4. LCMS ESI(m/z): 858.5  $[\text{M}+\text{H}]^+$ ; 856.5  $[\text{M}-\text{H}]^-$

25 30 **Generic synthesis description**


Synthesis of phosphor 2-chloro-1,3,2-oxazaphospholidine:  $\text{PCl}_3$  (1eq) was dissolved in toluene, cooled to 0 °C (ice bath) and a solution of **P5-L** (1eq) and NMM (2.1eq) in toluene was added dropwise. The reaction mixture was stirred at room temperature, and then cooled to -72 °C. Precipitates was filtered under argon, washed with toluene and filtrate was

concentrated at 40 °C at reduce pressure (*Schlenk technique*). The residue was dissolved in THF and used in the next step.

To a solution of 5'-ODMT-LNA nucleoside (1eq) in THF (and Pyridine in case of G nucleoside), NEt<sub>3</sub> (7eq) was added. The reaction mixture cooled to -70 °C and the solution 5 of phosphor 2-chloro-1,3,2-oxazaphospholidine (2.5eq) was added dropwise. The reaction mixture was stirred for at room temperature. EtOAc was added and the reaction mixture was extracted with sat. NaHCO<sub>3</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by column chromatography.


*Structure figures of the LNA monomers*


10



The following LNA-oxazaphospholine LNA monomers were synthesized using the method disclosed in Oka et al., J. Am. Chem. Soc. 2008; 16031-16037:

15





The above LNA monomers were used in oligonucleotide synthesis and shown to give  
 5 stereocontrolled phosphoramidite LNA oligonucleotides as determined by HPLC.

### Example 2

The following LNA oligonucleotides targeting Myd88 are synthesized.

$A_x^{mC}T_xG_xC_xT_xT_xT_xC_xC_xA_xC_xT_x^{mC}T_xG$  (Parent #1) (SEQ ID NO 1)

10  $A_x^{mC}T_xG_xC_xT_xT_xT_xC_xC_xA_xC_xT_x^{mC}T_xG$  (Parent #1)

$A_x^mC_xT_xG_xC_sT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #2)  
 $A_x^mC_xT_xG_xC_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #3)  
 $A_x^mC_xT_xG_xC_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #4)  
 $A_x^mC_xT_xG_xC_xT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #5)  
**5**  $A_x^mC_xT_xG_xC_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #6)  
 $A_x^mC_xT_xG_xC_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #7)  
 $A_x^mC_xT_xG_xC_sT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #8)  
 $A_x^mC_xT_xG_xC_sT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #9)  
 $A_x^mC_xT_xG_xC_sT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #10)  
**10**  $A_x^mC_xT_xG_xC_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #11)  
 $A_x^mC_xT_xG_xC_rT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #12)  
 $A_x^mC_xT_xG_xC_rT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #13)  
 $A_x^mC_xT_xG_xC_rT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #14)  
 $A_x^mC_xT_xG_xC_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #15)  
**15**  $A_x^mC_xT_xG_xC_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #16)  
 $A_x^mC_xT_xG_xC_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #17)  
 $A_x^mC_xT_xG_xC_sT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #18)  
 $A_x^mC_xT_xG_xC_sT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #19)  
 $A_x^mC_xT_xG_xC_sT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #20)  
**20**  $A_x^mC_xT_xG_xC_sT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #21)  
 $A_x^mC_xT_xG_xC_sT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #22)  
 $A_x^mC_xT_xG_xC_rT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #23)  
 $A_x^mC_xT_xG_xC_rT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #24)  
 $A_x^mC_xT_xG_xC_rT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #25)  
**25**  $A_x^mC_xT_xG_xC_rT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #26)  
 $A_x^mC_xT_xG_xC_rT_xT_xT_xC_xC_xA_xC_xT_x^mC_xT_xG$  (Comp #27)

Capital letters are beta-D-oxy LNA nucleosides, small letters are DNA nucleosides

Subscript x = randomly incorporated phosphorothioate linkage from a racemic mixture of Rp  
**30** and Sp monomers.

Subscript s = stereocontrolled phosphoramidite linkage from a Sp monomer

Subscript r = stereocontrolled phosphoramidite linkage from a Rp monomer

Superscript m preceding a capital C represents 5-methyl cytosine LNA nucleoside

**Example 3**

Parent compound #1 has been determined as a hepatotoxic in mice. Compounds #1 – 27# are evaluated for their hepatotoxicity in an *in vivo* assay: 5 NMRI female mice per group are used, 15mg/kg of compound are administered to each mouse on days 0, 3, 7, 10 and 14, 5 and sacrificed on day 16. Serum ALT is measured. Hepatotoxicity may also be measured as described in EP 1 984 381, example 41 with the exception that NMRI mice are used, or using an *in vitro* hepatocyte toxicity assay.

**Example 4**

10 The following LNA oligonucleotides identified as toxic in Seth et al J. Med. Chem 2009, 52, 10-13 are synthesized.

T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>x</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Parent #28) (SEQ ID NO 2)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #29)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>x</sub>g<sub>x</sub>g<sub>s</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #31)  
 15 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>x</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>s</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #32)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>s</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #33)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>s</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #34)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>s</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>s</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #35)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>x</sub>g<sub>x</sub>g<sub>s</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>s</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #36)  
 20 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>r</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #37)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>r</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #38)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>r</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>r</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #39)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>x</sub>g<sub>x</sub>g<sub>s</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>r</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #40)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>r</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>s</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #41)  
 25 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>s</sub>g<sub>x</sub>g<sub>s</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>r</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #42)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>r</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #43)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>x</sub>g<sub>x</sub>g<sub>r</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #44)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>x</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>r</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #45)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>r</sub>g<sub>x</sub>g<sub>r</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #46)  
 30 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>r</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>r</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #47)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>r</sub>g<sub>x</sub>g<sub>r</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>r</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #48)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>x</sub>g<sub>x</sub>g<sub>r</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>r</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #49)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>r</sub>g<sub>x</sub>g<sub>s</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>x</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #50)  
 T<sub>x</sub><sup>m</sup>C<sub>x</sub>a<sub>x</sub>t<sub>r</sub>g<sub>x</sub>g<sub>x</sub>c<sub>x</sub>t<sub>x</sub>g<sub>x</sub>c<sub>s</sub>a<sub>x</sub>g<sub>x</sub><sup>m</sup>C<sub>x</sub>T (Comp #51)

$T_x^mC_xa_xt_rg_xg_sc_xt_xg_xc_saxg_x^mC_xT$  (Comp #52)

$T_x^mC_xa_xt_xg_xg_rc_xt_xg_xc_saxg_x^mC_xT$  (Comp #53)

$T_x^mC_xa_xt_rg_xg_sc_xt_xg_xc_ra_xg_x^mC_xT$  (Comp #54)

$T_x^mC_xa_xt_rg_xg_rc_xt_xg_xc_saxg_x^mC_xT$  (Comp #55)

5 Capital letters are beta-D-oxy LNA nucleosides, small letters are DNA nucleosides  
Subscript x = randomly incorporated phosphorothioate linkage from a racemic mixture of Rp and Sp monomers.  
Subscript s = stereocontrolled phosphoramidite linkage from a Sp monomer  
Subscript r = stereocontrolled phosphoramidite linkage from a Rp monomer  
10 Superscript m preceding a capital C represents 5-methyl cytosine LNA nucleoside

#### Example 5

Parent compound #28 has been determined as a hepatotoxic in mice. Compounds #28 – 27# are evaluated for their hepatotoxicity in an *in vivo* assay: 5 NMRI female mice per group  
15 are used, 15mg/kg of compound are administered to each mouse on days 0, 3, 7, 10 and 14, and sacrificed on day 16. Serum ALT is measured. Hepatotoxicity may also be measured as described in EP 1 984 381, example 41 with the exception that NMRI mice are used, or using an *in vitro* hepatocyte toxicity assay.

20 **Example 6. Tolerance and tissue content of compound libraries with 3 fixed PS internucleoside linkages *in vivo*.**  
C57BL6/J mice (5animals/gr) were injected iv on day 0 with a single dose saline or 30 mg/kg LNA-antisense oligonucleotide in saline (seq ID # 1, 10, or 14) and sacrificed on day 8.  
25 Serum was collected and ALT was measured for all groups. The oligonucleotide content was measured in the LNA dosed groups using ELISA method.

#### Conclusions:

The hepatotoxic potential (ALT) for the subgroups of LNA oligonucleotides where 3 phosphorothioate internucleoside linkages are fixed in either S (Comp #10) or R (Comp #14)  
30 configuration was compared to the ALT for parent mixture of diastereoisomers (Comp #1) with all internucleoside linkages as mixtures of R and S configuration. It is seen (figure 3) that for one subgroup (Comp #14) the ALT readout is significantly lower than for the parent mixture (Comp #1) and for the other subgroup of compounds (Comp #10) ALT reading is similar to parent. Moreover, the liver uptake profile (figure 4a) show that the subgroup of  
35 LNA oligonucleotides with low ALT readout (Comp #14) is taken up into the liver to the same

extend as the parent LNA mixture (Comp #1) whereas the other subgroup (Comp #10) with ALT comparable to the parent mixture (Comp #1) is taken up less into the liver. Kidney uptake (figure 4b) is similar for parent LNA (Comp #1) and one subgroup (Comp #10) and higher for the other subgroup of LNA oligonucleotides (Comp #14). Uptake into the spleen is 5 similar for all 3 groups of compounds (figure 4c). Generally it is seen that fixing the stereochemistry in some positions and thereby generating a subgroup of LNA oligonucleotides induces differences for properties such as uptake and hepatotoxic potential compared to the parent mixture of LNA oligonucleotides.

## 10 Materials and Methods:

### Experimental design:

**Table 2**

Groups	Compounds	Day 1	Day 2	Day 3	Day 5	Day 8
1	Saline	Body weight Dosing	Body weight	Body weight	Body weight	Blood Body weight Termination
2	Comp #1 30mg/kg	Body weight Dosing	Body weight	Body weight	Body weight	Blood Body weight Termination
3	Comp #10 30mg/kg	Body weight Dosing	Body weight	Body weight	Body weight	Blood Body weight Termination
4	Comp #14 30mg/kg	Body weight Dosing	Body weight	Body weight	Body weight	Blood Body weight Termination

15 *Dose administration.* C57BL/6J Bom female animals, app. 20 g at arrival, were dosed with 10 ml per kg BW (according to day 0 bodyweight) *i.v.* of the compound formulated in saline or saline alone according to Table 2.

Sampling of liver and kidney tissue. The animals were anaesthetised with 70% CO<sub>2</sub>-30% O<sub>2</sub> and sacrificed by cervical dislocation according to Table 2. One half of liver and one kidney was frozen and used for tissue analysis.

20 Oligonucleotide content in liver and kidney was measured by sandwich ELISA method. ALT levels were measured

**Example 7 RNase H activity of chirally defined phosphorothioate LNA gapmers.**

The parent compound used, 3833 was used:

**5'- G<sub>s</sub> <sup>m</sup>C<sub>s</sub>a<sub>s</sub>t<sub>s</sub>t<sub>s</sub>g<sub>s</sub>g<sub>s</sub>t<sub>s</sub>a<sub>s</sub>t<sub>s</sub>T<sub>s</sub> <sup>m</sup>C<sub>s</sub>A -3' (SEQ ID NO 3)**

5 Wherein capital letters represent beta-D-oxy-LNA nucleosides, lower case letters represent DNA nucleosides, subscript s represents random s or r phosphorothioate linkages (not chirally defined during oligonucleotide synthesis), and superscript m prior to C represents 5-methyl cytosine LNA nucleoside.

10 A range of fully chirally defined variants of 3833 were designed with uniques patterns of R and S at each of the 12 internucleoside positions, as illustrated by either an S or an R. The RNaseH recruitment activity and cleavage pattern was determined using human RNase H, and compared to the parent compound 3833 (chirality mix) as well as a fully phosphodiester linked variant of 3833 (full PO), and a 3833 compound which comprises of phosphodiester linkages within the central DNA gap region and random PS linkages in the LNA flank (PO gap).

15 Compounds:

Oligo no.	Chirality of nucleo base linkages											
	1	2	3	4	5	6	7	8	9	10	11	12
16614	S	R	S	R	R	S	R	S	S	S	R	R
16615	S	R	S	S	R	S	R	S	R	S	S	S
16617	S	R	S	R	S	S	R	R	R	S	R	R
16618	S	R	R	S	S	S	R	S	S	S	R	R
16620	S	R	R	S	R	R	R	R	S	S	S	R
16621	S	R	R	S	S	S	R	R	R	S	S	S
16622	S	R	S	R	R	R	R	S	S	R	S	R
16623	S	S	R	R	S	S	S	R	S	R	S	S
16625	S	R	S	S	S	S	S	R	S	R	R	S
16626	S	S	S	S	S	S	R	R	S	S	R	S
16627	S	R	S	S	S	S	S	R	R	R	R	S
16629	S	R	R	R	R	S	S	R	S	S	S	S
16631	S	R	R	R	S	R	R	S	S	R	S	S
16633	R	S	R	S	S	R	R	S	R	R	S	S
16635	R	S	S	R	S	R	S	R	R	R	R	R
16636	S	R	R	R	S	R	R	R	R	S	R	S
16639	S	S	S	R	R	R	S	S	R	S	S	R
16641	S	S	S	S	R	R	R	S	R	R	R	R



All of the compounds were assessed in a single experiment except where marked \* when a separate experiment was performed

**Experimental:**

5 **LNA oligonucleotide mediated cleavage of RNA by RNase H1(recombinant human).**

LNA oligonucleotide 15 pmol and 5'fam labeled RNA 45 pmol was added to 13 µL of water. Annealing buffer 6 µL (200 mM KCl, 2 mM EDTA, pH 7.5) was added and the temperature was raised to 90 °C for 2 min. The sample was allowed to reach room temperature and added RNase H enzyme (0,15 U) in 3 µL of 750 mM KCl, 500 mM Tris-HCl, 30 mM MgCl<sub>2</sub>,

10 100 mM dithiothreitol, pH 8.3). The sample was kept at 37°C for 30 min and the reaction was stopped by adding EDTA solution 4 µL (0.25 M).

**AIE-HPLC of cleaved RNA samples**

The sample 15 µL was added to 200 µL of buffer A (10 mM NaClO<sub>4</sub>, 1 mM EDTA, 20 mM TRIS-HCL pH 7.8). The sample was subjected to AIE – HPLC injection column 50 µL(

15 Column DNA pac 100 2x250, gradient 0 min. 0.25 mL/min. 100 % A, 22 min. 22 % B(1 mM NaClO<sub>4</sub>, 1 mM EDTA, 20 mM TRIS-HCL pH 7.8), 25 min. 0.25 mL/min. 100 % B, 30 min. 0.25 mL/min. 100 % B, 31 min. 0. 5 mL/min. 0 % B, 35 min. 0. 25 mL/min. 0 % B, 40 min. 0. 25 mL/min. 0 % B. Signal detection fluorescens emission at 518 nm exitation at 494 nm.

**Results**

20 LNA oligonucleotide with the sequence G<sup>m</sup>CattggtatT<sup>m</sup>CA all phosphorus linkages thiolated. The specific chirality of the thiophosphate in the linkages are noted. Where nothing are noted the chirality are a mix of R and S. Under the AIE-HPLC retention time the

percentage's the peaks areas of the sum the all peak areas are listed. The ranking number of the activity of the different LNA-oligonucleotides are calculated from the % of full length

25 RNA left after the enzyme reaction the chirality mixed LNA oligonucleotide 3833 divided with what was left of the RNA for the other LNA oligonucleotides.

Oligo no.	AIE HPLC retention time (% of total )						Full length %	Full length 3833/chiral full length 3833
	11,05	11,367	11,742	12,3	12,75	12,942	15,017	
16614	1,9	19,3	3,5	63,4	0,0	0,0	11,9	4,4
16615								
16617	0,7	18,6	4,1	44,4	5,8	7,0	19,5	2,7
16618	2,2	16,1	6,1	45,9	5,1	8,1	16,5	3,2

16620	1,1	8,8	14,5	26,4	4,0	31,4	13,9	3,8
16621	2,2	1,8	32,9	37,4	0,0	11,5	14,2	3,7
16622	2,3	57,1	15,5	16,7	1,6	2,1	4,7	11,2
16623	2,8	3,7	22,9	60,7	1,7	3,6	4,7	11,2
16625	2,7	3,2	20,7	28,9	2,8	20,6	21,1	2,5
16626	1,3	3,2	4,6	34,0	6,0	30,1	20,9	2,5
16627	1,8	3,8	26,4	19,0	4,2	29,8	15,0	3,5
16629	1,7	2,4	36,3	38,6	2,6	5,7	12,8	4,1
16631	2,6	55,3	7,8	6,5	14,9	3,8	9,2	5,7
16633	0,0	50,3	7,1	4,8	6,4	18,8	12,5	4,2
16635	1,8	7,2	64,9	7,1	11,1	4,0	3,9	13,5
16636	2,1	3,8	8,9	6,4	27,9	11,6	39,3	1,3
16639	3,8	17,9	71,3	5,3	0,0	0,0	1,7	30,6
16641	1,9	41,7	10,3	10,7	2,5	13,5	19,4	2,7
16645	2,2	14,1	39,8	8,6	0,0	19,2	16,0	3,3
16648	1,2	3,3	22,2	55,7	1,8	2,6	13,2	3,9
16649	2,4	37,4	3,7	28,2	7,6	0,0	20,8	2,5
16650	1,3	5,6	5,6	58,3	0,0	22,3	6,8	7,7
16652	2,8	3,3	10,4	5,1	9,7	43,0	25,8	2,0
16655	0,0	3,5	3,8	20,2	4,7	21,2	46,5	1,1
16657	0,0	12,2	73,4	3,5	7,8	0,0	3,1	16,8
16658	0,0	15,9	34,2	37,0	0,9	2,4	9,6	5,5
16660	0,0	0,0	0,0	0,0	0,0	0,0	100,0	0,5
16663	0,0	4,5	38,3	25,9	7,5	4,9	19,0	2,7
16666	0,0	2,0	76,0	3,7	0,0	0,0	18,3	2,9
16667	0,0	31,5	30,1	25,5	0,0	9,3	3,7	14,3
16668	0,0	4,7	4,7	61,3	0,0	21,9	7,5	7,0
16669	0,0	3,7	76,3	6,4	1,9	2,6	9,1	5,7
16671								
16673	0,0	9,1	15,7	31,1	0,0	3,7	40,4	1,3
16674	0,0	0,0	0,0	7,8	0,0	0,0	92,2	0,6
16675	0,0	15,4	20,5	25,3	4,0	21,9	12,9	4,1
16676	0,0	1,6	29,2	33,1	0,0	17,2	18,9	2,8
16677	2,1	36,5	7,0	47,6	0,0	5,2	1,6	32,4
16683	1,5	17,8	34,3	20,2	2,8	2,3	20,9	2,5
16684	1,2	13,6	1,6	35,4	8,6	0,0	39,5	1,3
16685	0,0	3,4	78,6	7,4	2,1	2,2	6,3	8,3
16687	1,1	54,8	8,9	7,4	1,0	6,8	19,9	2,6
16688	1,1	16,8	55,1	3,4	6,3	12,1	5,2	10,1
16692	0,0	4,4	33,2	51,1	3,0	5,9	2,4	21,5
16693	0,0	4,4	30,4	28,7	0,0	28,9	7,6	6,8
16694	0,0	5,2	37,6	20,8	2,2	17,3	16,9	3,1
16697								

16699	1,5	1,6	17,5	19,3	6,8	9,0	44,3	1,2
16701	0,0	4,2	6,4	44,2	0,0	29,4	15,7	3,3
16702	0,0	27,3	20,4	22,9	1,2	8,7	19,5	2,7
16704	0,0	3,2	52,4	3,3	1,4	2,8	36,9	1,4
16709	8,5	31,4	4,1	2,3	8,7	25,0	20,0	2,6
17298	0,0	12,0	25,1	44,4	4,1	11,7	2,7	19,2
17299								
17300								
17301	1,8	17,2	2,7	4,7	8,9	16,2	48,5	1,1
3833	1,0	6,8	13,7	11,1	3,9	11,2	52,3	1,0
3833							10	1
18946	2,4	8,3	29,9	18,3	10,9	10,6	19,6	0,5
18947	0,0	8,8	34,0	21,6	10,5	10,5	14,6	0,7

## Conclusion

The chirality of the phosphorothioate linkages of the LNA oligonucleotide are randomly chosen except for the last 5' coupling where the S chirality were selected and the LNA oligonucleotides where spot chirality was chosen 17298-17301. The full diester and diester only in the gap version of the LNA oligonucleotide have less activity than the mixed chiral version 3833. The chiral sequence enhances the activation and cleavage of the RNA. For most of the specific chiral LNA oligonucleotides the activation of RNaseH1 worked better than for the chirality mixed 3833. The best of the specific sequences initiated substantial more cleavage of RNA than 3833 (98.4 % versus 47.7 % after 30 minutes). A characteristic of each of the specific LNA oligonucleotides are their unique cleavage pattern of the RNA varying form one to several cleavage points.

## Example 8 In vitro toxicity screening in primary hepatocytes

15 Mouse liver perfusion  
 Primary mouse hepatocytes were isolated from 10- to 13-week old male C57Bl6 mice by a retrograde two-step collagenase liver perfusion. Briefly, fed mice were anaesthetized with sodium pentobarbital (120 mg/kg, i.p.). Perfusion tubing was inserted via the right ventricle into the v. cava caudalis. Following ligation of the v. cava caudalis distal to the v. iliaca communis, the portal vein was cut and the two-step liver perfusion and cell isolation was performed. The liver was first perfused for 5 min with a pre-perfusing solution consisting of calcium-free, EGTA (0.5 mM)-supplemented, HEPES (20 mM)-buffered Hank's balanced salt solution, followed by a 12-min perfusion with NaHCO3 (25 mM)-supplemented Hank's solution containing CaCl2 (5 mM) and collagenase (0.2 U/ml; Collagenase Type II,

Worthington). Flow rate was maintained at 7 ml/min and all solutions were kept at 37°C. After in situ perfusion, the liver was excised, the liver capsule was mechanically opened, the cells were suspended in William's Medium E (WME) without phenol red (Sigma W-1878), and filtered through a set of nylon cell strains (40- and 70-mesh). Dead cells were removed 5 by a Percoll (Sigma P-4937) centrifugation step (percoll density: 1.06 g/ml, 50g, 10 min) and an additional centrifugation in WME (50xg, 3 min).

### Compounds used

$5' - \text{mC}_x \text{A}_x \text{mC}_x \text{a}_x \text{t}_x \text{t}_x \text{c}_x \text{c}_x \text{t}_x \text{t}_x \text{g}_x \text{c}_x \text{t}_x \text{mC}_x \text{T}_x \text{G}-3'$	(Parent #56)
$5' - \text{mC}_x \text{A}_x \text{mC}_x \text{a}_x \text{t}_x \text{t}_s \text{c}_x \text{c}_x \text{t}_x \text{t}_s \text{g}_x \text{c}_x \text{t}_s \text{mC}_x \text{T}_s \text{G}-3'$	(Comp #57)
$5' - \text{mC}_x \text{A}_x \text{mC}_x \text{a}_x \text{t}_x \text{t}_r \text{c}_x \text{c}_x \text{t}_x \text{t}_r \text{g}_x \text{c}_x \text{t}_r \text{mC}_x \text{T}_r \text{G}-3'$	(Comp #58)
$5' - \text{mC}_x \text{A}_x \text{mC}_x \text{a}_x \text{t}_x \text{t}_s \text{c}_s \text{c}_x \text{t}_x \text{t}_s \text{g}_s \text{c}_x \text{t}_x \text{mC}_x \text{T}_x \text{G}-3'$	(Comp #59)
$5' - \text{mC}_x \text{A}_x \text{mC}_x \text{a}_x \text{t}_x \text{t}_r \text{c}_r \text{c}_x \text{t}_x \text{t}_r \text{g}_r \text{c}_x \text{t}_x \text{mC}_x \text{T}_x \text{G}-3'$	(Comp #60)

10 Capital letters are beta-D-oxy LNA nucleosides, small letters are DNA nucleosides  
 Subscript x = randomly incorporated phosphorothioate linkage from a racemic mixture of Rp and Sp monomers.  
 Subscript s = stereocontrolled phosphoramidite linkage from a Sp monomer  
 Subscript r = stereocontrolled phosphoramidite linkage from a Rp monomer  
 15 Superscript m preceding a capital C represents 5-methyl cytosine LNA nucleoside.

### Hepatocyte culturing

For cell culture, primary mouse hepatocytes were suspended in WME supplemented with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (0.1 mg/ml) at a density of approx. 5 20  $\times 10^6$  cells/ml and seeded into collagen-coated 96-well plates (Becton Dickinson AG, Allschwil, Switzerland) at a density of  $0.25 \times 10^6$  cells/well. Cells were pre-cultured for 3 to 4h allowing for attachment to cell culture plates before start of treatment with oligonucleotides. Oligonucleotides dissolved in PBS were added to the cell culture and left on the cells for 3 days. Cytotoxicity levels were determined by measuring the amount of 25 Lactate dehydrogenase (LDH) released into the culture media using a Cytotoxicity Detection Kit (Roche 11644793001, Roche Diagnostics GmbH Roche Applied Science Mannheim, Germany) according to the manufacturer's protocol. For the determination of cellular ATP levels we used the CellTiter-Glo® Luminescent Cell Viability Assay (G9242, Promega Corporation, Madison WI, USA) according to the manufacturer's protocol. Each sample was 30 tested in triplicate.

### Target knock-down Analysis

mRNA purification from mouse hepatocytes RNeasy 96 Kit (Qiagen, Hombrechtikon, Switzerland) including an RNase free DNase I treatment according to the manufacturer's

5 instructions. cDNA was synthesized using iScript single strand cDNA Synthesis Kit (Bio-Rad Laboratories AG, Reinach, Switzerland). Quantitative real-time PCR assays (qRT-PCR) were performed using the Roche SYBR Green I PCR Kit and the Light Cycler 480 (Roche Diagnostics, Rotkreuz, Switzerland) with specific DNA primers. Analysis was done by the ΔCt threshold method to determine expression relative to RPS12 mRNA. Each analysis  
10 reaction was performed in duplicate, with two samples per condition. The results are shown in figures 5 & 6. Compounds #58 and #60 have significantly reduced toxicity whilst retaining effective antisense activity against the target (Myd88). These compounds comprise Rp stereodefined phosphorothioate linkages.

### 15 Example 9 Nephrotoxicity screening assay

The same compounds as used in example 6 and 8 were used in the following RPTEC-TERT1 culture, oligonucleotide treatment and viability assay:

20 RPTEC-TERT1 (Evercyte GmbH, Austria) were cultured according to the manufacturer's instructions in PTEC medium (DMEM/F12 containing 1% Pen/Strep, 10 mM Hepes, 5.0 µg/ml human insulin, 5.0 µg/ml human transferrin, 8.65 ng/ml sodium selenite, 0.1µM hydrocortisone, 10 ng/ml human recombinant Epidermal Growth Factor, 3.5µg/ml ascorbic acid, 25ng/ml prostaglandin E1, 3.2pg/ml Triiodo-L-thyronine and 100 µg/ml Geneticin).  
25 For viability assays, PTEC-TERT1 were seeded into 96-well plates (Falcon, 353219) at a density of  $2 \times 10^4$  cells/well in PTEC medium and grown until confluent prior to treatment with oligonucleotides. Oligonucleotides were dissolved in PBS and added to the cell culture at a final concentration of 10 or 30 µM. Medium was changed and oligonucleotides were added fresh every 3 days. After 9 days of oligonucleotide treatment, cell viability was  
30 determined by measurement of cellular ATP levels using the CellTiter-Glo® Luminescent Cell Viability Assay (G7571, Promega Corporation, Madison WI, USA) according to the manufacturer's protocol. The average ATP concentration and standard deviation of triplicate wells were calculated. PBS served as vehicle control.

The results are shown in Figure 8. Compound #10 shows reduced nephrotoxicity as compared to the non-stereospecified compound #1 and compound #14. Stereospecified compounds #57, #58, #60 show significantly reduced nephrotoxicity as compared to the parent compound (#56).

5

**Example 10 Mismatch Specificity of chirally defined phosphorothioate LNA gapmers.**

The experimental procedure used was as described in example 7, with the exception that alternative RNA substrates were used which introduced a mismatch at various positions as compared to the parent 3833 compound. The RNaseH activity against the perfect match

10 RNA substrate and the mismatch RNA substrates was determined.

Table 3: Effect of mismatches on RNaseH activity of 3833.

RNA: SEQ ID	RNA Substrate	TM up	Tm down	% full length
520	ACAGAAUACCAAUUGCACAGA	59.5	59.4	39.1
6	UGAGAAUACCAAUUGCUAAGU	57.8	59.8	
7	CAGGAAUACCAAUUGCAGAGA	59.2	61.8	58.3
8	AGUGGAAUACCAAUUGCUGCAG	53.4	55.7	54.6
9	UUUGGAAUACCAAUUGCAGUAGG	54.1	57.1	60.7
10	UCUGAGUACCAAUGCCAUGA	55.0	55.5	43.7
11	GCUGAAUGCCAAUGCUGAGU	56.9	57.6	67.4
12	UCUGAAUACCGAUGCUUUAA	57.3	58.0	42.8
13	UCUGAAUACCAUGUGCUUUAA	56.0	57.7	43.9
14	CUUGUAAUACCAAUUGCUAUAA	51.9	52.5	48.5
15	AAAGAAUACCAAUGUUCUCU	49.2	49.8	
16	UAUGAAUACCAUUGUCUUAU	40.5	41.4	72.0
17	CCGAUUGCCAAUUGCAGAGUU	57.1	58.0	75.2
18	GAUGAAAUACCAAUGUUAACU	39.6	40.8	
19	CUGAAUACCAAUUGCUGAACUU	59.0	59.9	49.9

Mismatches are shown by use of a larger font size. RNaseH cleavage analysed after 30 minutes. The cleavage products changes with the position of the mismatch.

Table 4: Effect of mismatches on RNaseH activity of stereodefined variants of 3833.

SEQ ID NO	RNA Substrate	LNA	% Full length	Relative activity of mis - match	Relative activity of full match
9	UU <u>UGGAUACCAAU</u> UAGG	3833	37,7	1	1
		16639	25,5	1,5	30,6
		16657	7,9	4,8	16,8
		16685	32,8	1,2	8,3
12	UCUGAAUAC <u>CCGAUG</u> CUUUAA	3833	53,0	1	1
		16650	71,7	0,7	7,7
		16668	79,5	0,7	7,0
13	UCUGAAUAC <u>CCAGUG</u> CUUUAA	3833	46,4	1	1
		16635	8,5	5,4	13,5
		16639	2,6	18,0	30,6
		16657	28,3	1,6	16,8
		16685	33,8	1,4	8,3

To a perfect match RNA substrate, chirally defined phosphorothioate oligonucleotides tend to activate RNaseH mediated cleavage of RNA more profound than the ASO with mixed chirality. However, chirally defined oligonucleotides of a chosen phosphorothioate (ASO) configuration can be found that have a marked reduced RNaseH cleavage of a mismatch RNA, highlighting the ability to screen libraries of chirally defined variants of an oligonucleotide to identify individual stereodefined compounds which have improved mismatch selectivity.

#### 10 Example 11

The parent compound used, 4358 was used:

5' G<sub>s</sub><sup>m</sup>C<sub>s</sub>a<sub>s</sub>g<sub>s</sub>c<sub>s</sub>a<sub>s</sub>t<sub>s</sub>c<sub>s</sub>c<sub>s</sub>t<sub>s</sub>G<sub>s</sub>T 3' (SEQ ID NO 5)

Wherein capital letters represent beta-D-oxy-LNA nucleosides, lower case letters represent DNA nucleosides, subscript s represents random s or r phosphorothioate linkages (not

chirally defined during oligonucleotide synthesis), and superscript m prior to C represents 5-methyl cytosine LNA nucleoside.

A range of fully chirally defined variants of 4358 were designed with unique patterns of R and S at each of the 11 internucleoside positions, as illustrated by either an S or an R. The

5 RNaseH recruitment activity and cleavage pattern was determined using human RNase H, and compared to the parent compound 4358 (chirality mix). The results obtained were as follows:

Oligo no.	Chirality of nucleobase linkages											% full length	Full length 4358/full length chiral
	1	2	3	4	5	6	7	8	9	10	11		
4358	Chirality mix											4.34	1.0
24387	S	S	S	S	S	S	S	S	S	S	S	4.30	1.01
24388	S	S	S	S	S	S	R	S	S	S	S	2.64	1.64
24389	S	S	S	R	S	S	S	S	S	S	S	4.01	1.08
24390	S	S	R	S	S	S	S	S	S	S	S	4.14	1.05

## CLAIMS

1. An LNA oligonucleotide comprising a central region (Y') of at least 5 or more contiguous nucleosides, and a 5' wing region (X') comprising of 1 – 6 LNA or 2' substituted nucleosides and a 3' wing region (Z') comprising of LNA 1 – 6 or 2' substituted nucleosides, wherein at least one of the internucleoside linkages of central region is stereodefined, and wherein the central region comprises both Rp and Sp internucleoside linkages; and wherein at least one of the LNA or 2' substituted nucleosides region (X') or (Z') is a beta-D-oxy LNA nucleoside.
2. The LNA oligonucleotide according to claim 1, wherein the 5' wing region (X') comprises of 1 – 6 LNA nucleosides and the 3' wing region (Z') comprises of LNA 1 – 6 nucleosides.
3. The LNA oligonucleotide of claim 1 or 2, wherein only 1, 2, 3, 4 or 5 of the internucleoside linkages of the central region (Y') are stereodefined phosphorothioate linkages, and the remaining internucleoside linkages are randomly Rp or Sp.
4. The LNA oligonucleotide of claim 1 or 2, wherein all of the internucleoside linkages of the central region (Y') are stereodefined phosphorothioate linkages.
5. The LNA oligonucleotide of any one of claims 1 – 4, wherein the central region (Y') comprises at least 5 contiguous phosphorothioate linked DNA nucleoside.
6. The LNA oligonucleotide of any one of claims 1 – 5, wherein the central region is at least 8 or 9 DNA nucleosides in length.
7. The LNA oligonucleotide according to any one of claims 1 – 6, wherein the internucleoside linkages of the central region (Y') are independently either Rp or Sp phosphorothioate linkages, and wherein at least one of the wing regions (X' or Z') comprises at least one stereodefined phosphorothioate linkage between an LNA nucleoside and a subsequent (3') nucleoside.
8. The LNA oligonucleotide of claim 7, wherein the other nucleoside of the nucleotide pair is other than DNA, such as nucleoside analogue, such as a further LNA nucleoside or a 2' substituted nucleoside.
9. The LNA oligonucleotide of any one of claims 1 - 8, wherein at least one of the internucleoside linkages linking the nucleosides of the central region (Y'), or linking the 3' nucleoside of region Y' with the first nucleoside of the 3' wing (X'), is a stereodefined phosphorothioate linkage.

10. The LNA oligonucleotide according to any one of claims 1 – 9, wherein each wing region comprises 1, 2 or 3 LNA nucleosides.
11. The LNA oligonucleotide according to any one of claims 1 – 10, wherein at least one wing region comprises a 2' substituted nucleoside.
12. The LNA oligonucleotide according to any one of claims 1 - 11, wherein the 2' substituted nucleoside is selected from the group consisting of 2'-O-MOE and 2'fluoro.
13. The LNA oligonucleotide according to any one of claims 1 – 12, wherein the nucleosides of the 5' (X') and 3' (Z') wing regions comprise or consist of LNA nucleosides/nucleotides, such as beta-D-oxy LNA nucleosides/nucleotides.
14. The LNA oligonucleotide according to any one of claims 1 – 13 wherein all the internucleoside linkages in the gapmer (X'-Y'-Z') are phosphorothioate linkages, such as stereodefined phosphorothioate linkages.
15. The LNA oligonucleotide according to any one of claims 1 – 14, wherein the gap region Y' comprises a DNA dinucleotide motif selected from the group consisting of cc, tg, tc, ac, tt, gt, ca and gc, wherein the internucleoside linkage between the DNA nucleosides of the dinucleotide is a stereodefined phosphoramidite linkage such as either a Sp or a Rp stereodefined phosphorothioate internucleoside linkage.
16. The LNA oligonucleotide according to any one of claims 1 – 15, wherein the LNA oligonucleotide has an enhanced human RNaseH recruitment activity as compared to an equivalent non stereoselective LNA oligonucleotide, for example using the RNaseH recruitment assays provided in example 7.
17. A conjugate comprising the stereoselective phosphorothioate LNA oligonucleotide of any one of claims 1 – 16 covalently attached to a non-nucleoside moiety.
18. A pharmaceutical composition comprising the stereodefined phosphorothioate LNA oligonucleotide of any one of claims 1 – 16 or the conjugate of any one –claim 17 and an a pharmaceutically acceptable solvent,(such as water or saline water), diluent, carrier, salt or adjuvant.
19. The stereodefined phosphorothioate LNA oligonucleotide of any one of claims 1 – 16 or the conjugate of any one claim 17, for use in medicine.

## FIGURES

Figure 1




Figure 2




Figure 3




Figure 4

a) Content in liver







Figure 4 (cont)

b) Content in kidney



c) Content in spleen





**Figure 5**

**Figure 6**

LNAs		Compound					control LNAs	
Readout	c [µM]	#56	#57	#58	#60	#59	-	+
LDH % control	1	160	173	91	85	174		
	3	184	198	93	98	217		
	10	210	223	112	112	256		
	30	246	225	116	112	257	114	256
ATP % control	1	71	59	87	81	64		
	3	59	45	83	71	53		
	10	50	40	78	69	44		
	30	43	32	75	64	37	101	28

### Severity



**Figure 7**

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2015/076967

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. C07H21/00 A61K31/712 A61K31/7125  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>W. B. WAN ET AL: "Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages", NUCLEIC ACIDS RESEARCH, vol. 42, no. 22, 14 November 2014 (2014-11-14), pages 13456-13468, XP055238014, GB ISSN: 0305-1048, DOI: 10.1093/nar/gku1115 cited in the application</p> <p>Whole document, in particular oligomers A3, A4, A7, A8, A11, A12, A15 and A16 in Table 1</p> <p>-----</p> <p style="text-align: center;">-/-</p>	1-16,18, 19
Y		17

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier application or patent but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
22 February 2016	29/02/2016
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Lécaillon, Jennifer

## INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2015/076967

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2014/118267 A1 (SANTARIS PHARMA AS [DK]) 7 August 2014 (2014-08-07) cited in the application	17
A	Whole document, in particular claims 12, 13, 15 and 17, examples 1, 4, 7 and 10, and pages 45-50 and 59 -----	1-16,18, 19
A	NATSUHISA OKA ET AL: "Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms", CHEMICAL SOCIETY REVIEWS, vol. 40, no. 12, 1 January 2011 (2011-01-01), page 5829, XP055114271, ISSN: 0306-0012, DOI: 10.1039/c1cs15102a the whole document -----	1-19
A	JEPSEN J S ET AL: "LNA-ANTISENSE RIVALS SIRNA FOR GENE SILENCING", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 7, no. 2, 1 January 2004 (2004-01-01) , pages 188-194, XP009083873, ISSN: 1367-6733 the whole document -----	1-19
2		

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No  
PCT/EP2015/076967

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 2014118267	A1 07-08-2014	AU 2014211406	A1 04-06-2015	CA 2893801 A1 07-08-2014